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Introduction {#sec001}
============

It is well-established that HIV-1 infects target cells by engaging its Envelope glycoprotein (a trimer of gp160, itself a heterodimer of gp120 and gp41) with host receptor CD4 \[[@ppat.1008359.ref001]\] and co-receptors CCR5 \[[@ppat.1008359.ref002]\] or CXCR4 \[[@ppat.1008359.ref003]\]. Subsequently, the receptor and co-receptor interactions trigger conformational changes in the gp41 transmembrane subunit, facilitating virus-cell fusion and the formation of a post-fusion, thermodynamically-stable six-helix bundle \[[@ppat.1008359.ref004]\]. Identifying elements that underpin the earliest stages of HIV-1 infection is a priority in the search for an HIV cure \[[@ppat.1008359.ref005]\]. Furthermore, numerous studies have highlighted the importance of cellular metabolism in T cell-mediated antiviral responses and control of viral infection \[[@ppat.1008359.ref006],[@ppat.1008359.ref007]\]. However, the role played by single-cell metabolic activity in cellular susceptibility to HIV-1 invasion has not been addressed.

Upon activation, T cells increase rates of glycolysis and oxidative phosphorylation to cope with higher energy demands associated with immune functions \[[@ppat.1008359.ref008]\]. Expression of the glucose transporter Glut1 is increased upon T cell activation and is required for post-entry HIV replication \[[@ppat.1008359.ref009]\]. Moreover, the Glut1-associated increased glycolytic flux has also been observed in HIV-1 infected cells \[[@ppat.1008359.ref010],[@ppat.1008359.ref011]\] and affects virus pathogenicity and production \[[@ppat.1008359.ref012]\]. More recently, it has been shown that basal glycolytic activity of CD4^+^ T cell subsets correlates with susceptibility to HIV-1 infection \[[@ppat.1008359.ref013]\]. The authors showed that chronic, suboptimal inhibition of glycolytic activity impairs HIV-1 infection in T cells, but it was unclear which stage of HIV-1 infection was affected \[[@ppat.1008359.ref013]\]. Pyruvate made from glycolysis may enter the citric acid cycle to yield biosynthetic intermediates (such as oxaloacetate and citrate) and reduced electron carriers (NADH and FADH~2~). Although in activated T cells most pyruvate is excreted as lactate, increased cytosolic levels of citrate and NAD^+^ are found \[[@ppat.1008359.ref014]\] suggesting that this pathway is still in use by activated T cells. Citrate is a precursor of cytosolic acetyl-CoA, which is required for cholesterol biosynthesis and a major determinant of cellular membrane architecture \[[@ppat.1008359.ref015]\].

Cholesterol is required for the formation and maintenance of liquid-ordered (Lo) membrane domains in addition to reducing membrane tension \[[@ppat.1008359.ref016],[@ppat.1008359.ref017]\]. Higher plasma membrane cholesterol content stretches lipid tails in Lo domains and a discontinuity within the bilayer is created at the phase boundary between Lo and liquid-disordered (Ld) domains, manifesting in line tension. In turn, enhanced membrane tension regulates membrane curvature. Hemifusion (i.e. the merging of contacting outer membrane leaflets without formation of a fusion pore) is regulated by membrane curvature---positive curvature negates the propensity of fusion pores to progress to full fusion, whereas negative curvature facilitates this process \[[@ppat.1008359.ref018],[@ppat.1008359.ref019]\]. Increased cholesterol establishes line tension between Lo and liquid disordered (Ld) domains and generates negative spontaneous curvature in support of fusion, whereas cholesterol depletion increases membrane tension, decreases line tension between Lo and Ld domains and enables positive spontaneous membrane curvature to disfavour fusion \[[@ppat.1008359.ref017],[@ppat.1008359.ref020]--[@ppat.1008359.ref023]\].

Membrane order, tension and curvature are significant contributors to several membrane-regulated processes in human cells important for viral infection, particularly enveloped virus entry (i.e. fusion and endocytosis) and egress \[[@ppat.1008359.ref024],[@ppat.1008359.ref025]\]. In addition, boundaries between cholesterol-enriched Lo and Ld microdomains are well-established determinants of successful entry for a range of viruses, including HIV-1 \[[@ppat.1008359.ref026]--[@ppat.1008359.ref029]\]. The phase boundaries between Lo and Ld domains are thought to represent the site of HIV-1 entry, which may be due to line tension derived from Lo and Ld boundaries which drive membrane bending needed to facilitate fusion \[[@ppat.1008359.ref021],[@ppat.1008359.ref027]\]. Intriguingly, it has been demonstrated that plasma membrane cholesterol content of dendritic cells, macrophages, and T cells in HIV-1-infected long-term non-progressors is substantially reduced compared to that of rapid progressors, and that the cellular cholesterol content correlates with the capacity of HIV-1 to spread \[[@ppat.1008359.ref030],[@ppat.1008359.ref031]\]. Therefore, an unexplored relationship may exist between the host cell metabolic state, cholesterol, and virus entry into cells.

A significant development in the study of cellular metabolism is the application of fluorescence-lifetime imaging microscopy (FLIM) in individual cells \[[@ppat.1008359.ref032],[@ppat.1008359.ref033]\]. FLIM provides resolution in single cell microenvironments that are missed by population-based or spectral methods. Here, we observed higher rates of HIV-1 fusion and infection in cells with high glycolytic activity, as reported by their ATP:ADP ratios and intracellular lactate concentrations, compared to cells with low glycolytic activity. Further analysis demonstrated that targeted inhibition of glycolysis by 2-deoxy-d-glucose (2-DG) drastically decreased HIV-1 fusion and infection. Multicolour real-time single virus tracking (SVT) revealed that HIV-1 entry is arrested at the stage of hemifusion in cells that are glycolytically inactive. 2-DG-treated cells displayed a loss of membrane cholesterol and addition of water-soluble cholesterol to these cells rescued HIV-1 fusion. Moreover, 2-DG treatment decreased membrane order and increased tension of cells as measured by FRET-based biosensor probes using FLIM. To further investigate the connection between membrane tension and HIV-1 entry, we developed a novel assay that combines FLIM and single virus tracking techniques to visualize and identify factors pivotal to HIV-1 infection at high-spatiotemporal resolution in single cells. Through this approach, we initially show that HIV-1 particles generate increased flux in global host-cell membrane tension that is, at least in part, CCR5-dependent. Furthermore, we illustrate that HIV-1 requires local decreases in membrane tension during the process of virus-cell fusion, which is prevented during the inhibition of glycolysis, yet rescued via cholesterol supplementation. Overall, our results demonstrate a functional link between the glycolytic activity of the host cell and the success of HIV-1-mediated virus-cell fusion, with an important role for membrane cholesterol establishing a favourable biophysical environment to facilitate virus entry.

Results {#sec002}
=======

Basal metabolic state is a determinant of HIV-1 infection in T cells and reporter cells {#sec003}
---------------------------------------------------------------------------------------

There is an inherent hierarchy in the susceptibility of CD4 T cell subsets to HIV-1 infection. Recent work observed that overall T cell subset metabolic activity correlates with susceptibility to replication by HIV pseudotyped with VSV-G envelope protein (HIV-1~VSV-G~-eGFP) \[[@ppat.1008359.ref013]\]. Here, we use TZM-bl and MT4 T cells that are homogeneous in metabolic state and have high glycolytic activity similar to activated CD4 T cells susceptible to HIV-1 infection \[[@ppat.1008359.ref034]\]. TZM-bl cells are highly susceptible to HIV-1~JR-FL~ infection, whereas MT4 T cells are highly susceptible to HIV-1~NL4.3~ as well as HIV-1~VSV-G~ infection. Importantly, TZM-bl cells report HIV-1 infection with high sensitivity through a β-Galactosidase-mediated enzymatic activity.

Initially, we observed a dependence of HIV-1 infection on glycolytic activity in MT4 T cells treated acutely (i.e. 2 hours) with 2-DG prior to infection with HIV-1~VSV-G~ ([Fig 1A](#ppat.1008359.g001){ref-type="fig"}). Additionally, when exposing MT4 T cells to HIV-1~NL4.3,~ we observed a similar inhibitory effect of 2-DG treatment on virus infection ([S1A Fig](#ppat.1008359.s001){ref-type="supplementary-material"}).

![Relative lactate and ATP/ADP concentrations in single cells correlate with HIV-1 infection.\
A.) Bar charts depicting % eGFP-expressing cells (i.e. mean of three independent experiments) as a marker of infection illustrating that acute treatment with increasing concentrations of2-DG for two hours led to reductions in HIV-1~VSV-G~ infection in human MT4 T cells. B.) Bar charts depicting % eGFP-expressing cells (i.e. mean of three independent experiments) as a marker of infection illustrating that acute treatment with increasing concentrations of oligomycin for two hours did not inhibit HIV-1~VSV-G~ infection in human MT4 T cells. C.) Approach to evaluate if basal, single-cell ATP:ADP ratio could predict HIV-1~JR-FL~ infection in TZM-bl cells. TZM-bl cells were seeded onto an Ibidi 8-well gridded dish and transiently transfected with metabolic sensing biosensors Laconic or Perceval. FLIM images of cells transiently expressing these biosensors were recorded, denoting the location of the cells on the grid. These cells were then treated with HIV-1~JR-FL,~ and after 48 hours a β-galactosidase assay was recorded on the same cells as a readout of infection. D.) (Top row) Representative images of β-galactosidase recorded 48 hours after HIV-1~JR-FL~ infection (left) and basal FLIM images of intracellular lactate biosensor Laconic-expressing TZM-bl cells taken before infection (right) illustrating cells with higher intracellular lactate concentrations (warm colours, solid white circle) were more likely to be infected by HIV-1~JR-FL~ (top row, solid white circle); scale bar 50μm. (Bottom Row) Representative images of β-galactosidase recorded 48 hours after HIV-1~JR-FL~ infection (left) and basal FLIM images of intracellular ATP:ADP biosensor Perceval-expressing TZM-bl cells taken before infection (right) illustrating cells with higher intracellular ATP:ADP concentrations (cool colours, solid white 1, 2 circle) were more likely to be infected by HIV-1~JR-FL~ (bottom row, solid white 1,2 and 3 circles); scale bar 50 μm. Built-in negative controls noted with dotted white circles (a, first row and a,b, second row) are presented in both cases (Laconic and Perceval expressing cells). Data depicted in bar charts are a mean of three experiments with at least 30 analysed cells per condition. \*\*\* p\<0.001 as determined by Student T test of three independent experiments.](ppat.1008359.g001){#ppat.1008359.g001}

Increased citrate and NAD^+^ levels in activated T cells suggests that glycolysis-derived pyruvate may be used for downstream energy production \[[@ppat.1008359.ref006]\]. Here, we tested whether global reductions in ATP synthesis, rather than the reduction of other biosynthetic intermediates of the TCA cycle, are responsible for the diminished HIV-1 infection observed upon glycolysis inhibition with 2-DG. Treatment with high concentrations of oligomycin, an inhibitor of the F~0~ proton channel of ATP synthase, failed to reduce HIV-1~VSV-G~ infection in MT4 cells ([Fig 1B](#ppat.1008359.g001){ref-type="fig"}), illustrating that deficiency in upstream biosynthetic intermediates rather than a global decrease in ATP production leads to reductions in HIV infection.

To determine how a cell's metabolic state correlates with HIV-1 infection, we employed fluorescence lifetime imaging microscopy (FLIM), which enables the quantification of the activity of metabolite reporters at the single cell level. We use FLIM as this methodology provides measurements that are independent of a fluorophore's concentration \[[@ppat.1008359.ref035]\], and increases the reporter's dynamic range ([S1B--S1E Fig](#ppat.1008359.s001){ref-type="supplementary-material"}) \[[@ppat.1008359.ref036]\].

[Fig 1C](#ppat.1008359.g001){ref-type="fig"} depicts our general strategy to determine if metabolic states could influence virus entry and subsequent infection. Briefly, we transiently transfected Perceval \[[@ppat.1008359.ref037]\], an established ratiometric reporter of the intracellular ATP:ADP ratio, or Laconic \[[@ppat.1008359.ref038]\], an intracellular lactate biosensor, to monitor glycolytic flux in TZM-bl cells via FLIM. As shown in [S1B--S1E Fig](#ppat.1008359.s001){ref-type="supplementary-material"}, treatment of TZM-bl cells with increasing concentrations of 2-DG led to stark changes in the fluorescence lifetime of both Perceval and Laconic in accordance with their biochemical properties, which have previously been described for Perceval (i.e. higher ATP/ADP ratios correspond to lower Perceval lifetimes) \[[@ppat.1008359.ref037]\] and Laconic (i.e. higher intracellular lactate concentrations correspond to higher Laconic lifetimes) \[[@ppat.1008359.ref038]\]. Treatment with 2-DG did not alter the intracellular pH during lifetime measurements, a factor known to distort lifetimes of fluorescent proteins ([S2B Fig](#ppat.1008359.s002){ref-type="supplementary-material"}). Furthermore, two-photon FLIM, a well-established method to decipher the dynamics of NAD(P)H metabolism in living cells \[[@ppat.1008359.ref039]\], showed robust decreases in the ratio of NAD(P)H~free~ vs. NAD(P)H~bound~ in MT4 cells upon 2-DG treatment ([S2A Fig](#ppat.1008359.s002){ref-type="supplementary-material"}, corresponding bar graph in [S2D Fig](#ppat.1008359.s002){ref-type="supplementary-material"}), therefore indicating similar decreases in glycolytic flux upon 2-DG treatment and that this decrease is not exclusive to TZM-bl cells in our study. Treatment of MT4 cells with 5 μM oligomycin did not lead to stark changes in this redox ratio, most likely owing to their pre-activated state ([S2C Fig](#ppat.1008359.s002){ref-type="supplementary-material"}).

Our approach emphasizing fluorescent lifetimes of metabolic biosensors allowed us to calculate relative ATP:ADP ratios or relative lactate concentrations (see [Methods](#sec009){ref-type="sec"}) prior to infection, and whether or not these calculated parameters could be predictive of cellular permissiveness to HIV-1 infection, as measured by β-galactosidase activity \[[@ppat.1008359.ref040]\]. Briefly, the β-galactosidase assay utilizes an X-gal stain to detect virus-infected cells as TZM-bls harbour the Tat-responsive reporter LacZ reporter for the detection of Tat-dependent β-galactosidase activities during viral infection. The seeding of cells onto gridded coverslips enabled single cells to be tracked over time. Interestingly, cells that possessed higher relative lactate concentrations ([Fig 1D](#ppat.1008359.g001){ref-type="fig"}, top row) or a higher relative ATP:ADP ratio ([Fig 1D](#ppat.1008359.g001){ref-type="fig"}, bottom row) were more likely to become infected by HIV-1~JR-FL~. These results shows that the correlation between glycolytic activity and HIV-1 infection holds true not only during drug treatment of bulk cells but also when accounting for differential baseline metabolic activity of individual cells.

Basal metabolic state is a determinant of HIV-1 fusion in reporter cells {#sec004}
------------------------------------------------------------------------

The separation between HIV-1~JR-FL~-infected and non-infected cells based on their ATP:ADP ratios and relative lactate concentrations in reporter cells prior to infection prompted us to determine the stage at which HIV-1 infection is inhibited. To determine if the preference for HIV-1 to infect glycolytically-active cells is based on pre- or post-fusion determinants in cells, we multiplexed our FLIM-based reporters into cells and used virus packaging a β-lactamase-Vpr fusion protein (BlaM-Vpr) \[[@ppat.1008359.ref041]\] ([Fig 2A](#ppat.1008359.g002){ref-type="fig"}), which provides a readout of viral access to the cytoplasm (virus-cell fusion). Briefly, the β-lactamase assay relies on the packaging of the β-lactamase enzyme into nascent HIV-1 virions, where subsequently fusion-positive cells are able to cleave the loaded cytoplasmic FRET-based CCF2 dye, changing the FRET profile readout. Importantly, the BlaM fluorescence profile is not skewed by the ATP:ADP ratio or lactate biosensors because the excitation profiles do not overlap.

![Relative lactate and ATP/ADP concentrations in single cells correlate with HIV-1 fusion.\
A.) Approach to evaluate if basal, single-cell ATP:ADP ratios or intracellular Lactate concentrations could predict HIV-1~JR-FL~ fusion. TZM-bl cells were seeded onto an Ibidi 8-well gridded dish and transiently transfected with metabolic sensing biosensors Laconic or Perceval. FLIM images of cells transiently expressing these biosensors were recorded, denoting the location of the cells on the grid. These cells were then treated with HIV-1~JR-FL.~ After 90 minutes, viruses were washed away and a β-lactamase assay was recorded on the same cells as a readout of HIV-1~JR-FL~ fusion. B.) Representative images of CCF2-loaded cells in Ibidi 8-well gridded dishes recorded 90 minutes after HIV-1~JR-FL~ infection (top row, white solid circles denoting red cells undergoing fusion) and basal FLIM images of intracellular lactate biosensor Laconic-expressing TZM-bl cells taken before HIV-1~JR-FL~ treatment (bottom row) illustrating cells with higher intracellular lactate concentrations (warm colours, solid white circles) were more likely to be scored fusion-positive for HIV-1~JR-FL~ fusion by the β-lactamase assay (bottom row); scale bar, in order of appearance: 200μm, 100μm, 50μm. Built-in controls of cells not undergoing fusion that in turn presented lower lifetimes (cold colours) are stressed with dotted circles C.) Representative images of CCF2-loaded cells in Ibidi 8-well gridded dishes recorded 90 minutes after HIV-1~JR-FL~ treatment (top row) and basal FLIM images of intracellular ATP:ADP biosensor Perceval-expressing TZM-bl cells taken before HIV-1~JR-FL~ treatment (bottom row) illustrating cells with higher intracellular ATP:ADP concentrations (cool colours, solid white circle) were more likely to be scored fusion-positive for HIV-1~JR-FL~ fusion by the β-lactamase assay (bottom row, solid white circle stressing a red fusion positive cells) scale bar, in order of appearance 100μm, 50μm. Data depicted in bar charts are a mean of three experiments with at least 30 analysed cells per condition. \*\*\* p\<0.001 as determined by Student T test of three independent experiments.](ppat.1008359.g002){#ppat.1008359.g002}

Interestingly, single cells with a higher relative lactate concentration were more likely to be fusion positive as determined by the BlaM assay than cells with a lower relative lactate concentration ([Fig 2B](#ppat.1008359.g002){ref-type="fig"}). Similarly, cells with a reportedly higher ATP:ADP ratio were more likely to be fusion positive than cells with a lower relative ATP:ADP ratio ([Fig 2C](#ppat.1008359.g002){ref-type="fig"}). Therefore, our data suggests that cells with a higher glycolytic flux are more likely to be infected by HIV-1~JR-FL~, and this bias for glycolytically-active cells occurs at the point of HIV-1 fusion.

Inhibition of glycolysis blocks HIV-1 fusion at hemifusion {#sec005}
----------------------------------------------------------

As we initially saw a potential dependence on HIV-1 entry into host cells with host cell glycolytic flux, we tested whether acute arrest of glycolysis via incubation with increasing concentrations of 2-DG would inhibit HIV-1 fusion as reported by the BlaM assay. Treatment of cells with increasing concentrations of 2-DG led to a reduction in both the ATP:ADP ratio and lactate levels in biosensor-expressing cells with minimal loss in cell viability as determined by propidium iodine staining ([S1 Fig](#ppat.1008359.s001){ref-type="supplementary-material"}, [S4A Fig](#ppat.1008359.s004){ref-type="supplementary-material"}).

Pre-treatment of TZM-bl cells with increasing concentrations of 2-DG resulted in dose-dependent decreases in the relative amounts of lactate and ATP:ADP and a concomitant inhibition of HIV-1~JR-FL~ fusion ([Fig 3A and 3B](#ppat.1008359.g003){ref-type="fig"}). Acute treatment with 100 mM 2-DG blocked HIV-1~JR-FL~ fusion by nearly 80%. Furthermore, we observed similar reductions in HIV-1~HXB2~ fusion in primary CD4+ T cells acutely pre-treated with 2-DG ([S3 Fig](#ppat.1008359.s003){ref-type="supplementary-material"}). Additionally, we similarly observed that increasing concentrations of 2-DG disrupted VSV-G-pseudotyped HIV-1 fusion. Acute glucose deprivation resulted in near-similar reductions in virus-cell fusion events ([S4B Fig](#ppat.1008359.s004){ref-type="supplementary-material"}), although remaining intracellular glycolytic intermediates and glucose at the time of starvation may explain why a more potent inhibition of viral fusion was not reached, as glycolysis may have been allowed to continue briefly after starvation conditions were initiated. Furthermore, acute treatment of TZM-bl cells with 2-DG did not lead to any visible alterations in surface expression of CD4 receptor or CCR5 co-receptor ([S4C Fig](#ppat.1008359.s004){ref-type="supplementary-material"}). Therefore, glycolysis appears to be a major regulator of successful HIV-1 fusion in human target cells.

![Addition of 2DG arrests HIV-1 fusion at the hemifusion stage.\
A.) (Left) Representative images of CCF2-loaded cells recorded 90 minutes after HIV-1~JR-FL~ infection in vehicle and incrementally increasing 2-DG treatment conditions; scale bar 50μm. (Right) Corresponding bar graph compiling data extracted from the β-lactamase assay and normalised to vehicle-treated control illustrating that increasing concentrations of 2-DG led to reductions in viral fusion for HIV-1~JR-FL.~ in TZM-bl cells (mean of three independent experiments). \*p\<0.5, \*\*p\<0.01 \*\*\* p\<0.001 as determined by one-way ANOVA. B.) (Left) Representative images of CCF2-loaded cells recorded 90 minutes after HIV-1~VSV-G~ infection in vehicle and incrementally increasing 2-DG treatment conditions; scale bar 50μm. (Right) Corresponding bar graph compiling data extracted from the β-lactamase assay and normalised to vehicle-treated control illustrating that increasing concentrations of 2-DG led to partial reduction in viral fusion for HIV-1~VSV-G~ in TZM-bl cells (mean of three independent experiments). \*p\<0.5, \*\*p\<0.01 \*\*\* p\<0.001 as determined by one-way ANOVA. C.) (Top row, left) Cartoon diagram illustrating the concept of single-particle tracking with double-labelled virions with DiD and eGFP-gag. Briefly, double-labelled virions entering via endocytosis will have their eGFP-gag signal infinitely diluted during endosomal fusion whilst DiD signal is retained in the endosome, which is mobile. Virions entering via plasma membrane fusion will have their DiD signal infinitely diluted in the plasma membrane whereas the eGFP-gag signal is retained and mobile. Hemifusion is denoted when DiD signal infinitely diluted in the plasma membrane whereas the eGFP-gag signal is retained and immobile. (Top row, right) Kinetics of the individual hemifusion events plotted as cumulative distributions as a function of time. (Bottom row, left) Representative panel of images illustrating doubled-labelled HIV-1~JRFL~ particles losing DiD signal (red) and maintaining immobile eGFP signal (green) when attempting fusion in 2-DG treated cells, suggesting arrest at hemifusion (n = 15, acquired during three independent experiments). (Bottom row, right) Bar chart representing the total number of HIV~JRFL~ double-labelled particles tracked for TZM-bl cells treated with 2DG (red bars) and without treatment (green bars). Only in cells without 2-DG treatment plasma membrane fusion was observed. Total number events tracked in control conditions: 217. Total number of events tracked in 2-DG-treated conditions: 236.](ppat.1008359.g003){#ppat.1008359.g003}

To further characterise how glycolytic inhibition abrogated HIV-1 fusion in TZM-bl cells, we tracked single virus particles upon exposure to cells. To accomplish this, we co-labelled particles with the lipophilic dye DiD, which incorporates into the viral lipid bilayer, and eGFP fused to Gag to identify the virus core. DiD loss from a particle marked by eGFP-Gag signals lipid mixing between viral and cellular membranes. Furthermore, differences between the surface area of the plasma membrane and endosomal membranes result in differential dilution of the lipophilic dye. As such, lipid mixing at the plasma membrane results in complete dilution of the dye and loss of fluorescent signal, whereas mixing at endosomal membranes has relatively little impact on the lipophilic dye's fluorescent signal ([Fig 3C](#ppat.1008359.g003){ref-type="fig"}). Irrespective of the initial site of lipid mixing, loss of eGFP-Gag signals that pore formation is complete and cytosolic disintegration of viral core has occurred.

During infection of TZM-bl cells, punctate structures of Gag-eGFP and the lipophilic dye DiD co-localize together at time = 0 sec and subsequently turn red (t~1/2~ = 10.25 minutes). This confirms previous studies showing that HIV-1~JR-FL~ particles enter TZM-bl cells via endocytosis, since Gag-GFP signal is lost while DiD signal (red) persists as it remains in the endosomal membrane ([S4D Fig](#ppat.1008359.s004){ref-type="supplementary-material"}) \[[@ppat.1008359.ref041],[@ppat.1008359.ref042]\]. In contrast, in TZM-bl cells treated with 2-DG (100 mM), double-positive (yellow) particles turn green over time ([Fig 3C](#ppat.1008359.g003){ref-type="fig"}), indicating DiD dilution at the plasma membrane in the absence of viral content release (Gag-GFP). Specifically, punctate structures of Gag-eGFP and the lipophilic dye DiD co-localize together at time = 0 sec and turn green with a t~1/2~ = 2.53 minutes). This process is suggestive of the hemifusion intermediate preceding full dilation of the fusion pore \[[@ppat.1008359.ref042]--[@ppat.1008359.ref044]\]. Moreover, the kinetics of lipid mixing at the plasma membrane corroborates previously reported analyses of hemifusion events \[[@ppat.1008359.ref043]\]. Interestingly, this analysis uncovered two distinct types of DiD disappearance events. One population exhibited a nearly-asymptotic loss of DiD fluorescence ([Fig 3C](#ppat.1008359.g003){ref-type="fig"}), whereas another population had a slow DiD fluorescence decay lasting up to 10 minutes or longer ([S4E Fig](#ppat.1008359.s004){ref-type="supplementary-material"}). We observed that 7% of single virions rapidly released their lipophilic marker into the plasma membrane, which is similar to previously reported SVT analyses of these events \[[@ppat.1008359.ref043]\]. In summary, these data suggest that cells treated with increasing concentrations of 2-DG display reduced levels of fused virus particles in reporter TZM-bl cell lines and that this arrest to fusion occurred at the hemifusion stage.

In previous studies we \[[@ppat.1008359.ref045]\] and others \[[@ppat.1008359.ref046],[@ppat.1008359.ref047]\] evaluated the impact of spinoculation during HIV-1 entry and fusion and its subsequent influence on directing HIV-1 entry to endosomes. To evaluate this potential influence, we conducted SVT experiments with and without spinoculation ([S5 Fig](#ppat.1008359.s005){ref-type="supplementary-material"}). Our results illustrate that, in non-spinoculated TZM-bl cells, both plasma membrane fusion and endosomal fusion may occur, yet when applying spinoculation protocols, we did not observe plasma membrane fusion events. All of our SVT experiments were performed without spinoculation protocols, enabling the subsequent analysis of membrane properties involved in viral fusion at the plasma membrane and in endosomes (see below). Therefore, the observed hemifusion arrest by 2-DG, in which DiD dye dissipates but Gag-GFP does not, is most likely occurring at the plasma membrane.

Single-cell metabolic state is linked to plasma membrane cholesterol content {#sec006}
----------------------------------------------------------------------------

Several studies have linked the inhibition of a variety of metabolic pathways to the availability of lipids in the plasma membrane \[[@ppat.1008359.ref048]--[@ppat.1008359.ref050]\], and several of which, including cholesterol, are important for successful virus entry \[[@ppat.1008359.ref026],[@ppat.1008359.ref029]--[@ppat.1008359.ref031]\]. To assess whether the inhibition of glycolysis was tied to the amount of plasma membrane cholesterol, we stained for cholesterol with Filipin III after treating cells acutely with increasing concentrations with 2-DG (see [Material and Methods](#sec009){ref-type="sec"}). Filipin has been shown to report cholesterol content in cellular membranes. Indeed, in both TZM-bl and MT4 cells, we noticed that acute treatment with 100mM 2-DG led to reductions in cholesterol by approximately 20% and 50% in T cells and reporter cells, respectively, as measured by flow cytometry ([Fig 4A and 4B](#ppat.1008359.g004){ref-type="fig"}). Immunofluorescence imaging further confirmed these results, illustrating substantial loss of cholesterol from the plasma membrane surface ([Fig 4A](#ppat.1008359.g004){ref-type="fig"}). Furthermore, treatment with 1mM methyl-β-cyclodextrin (MBCD), an acute cholesterol depletion reagent \[[@ppat.1008359.ref051]\], led to similar reductions in cholesterol staining signal as 2-DG ([S6A Fig](#ppat.1008359.s006){ref-type="supplementary-material"}). Interestingly, treatment with increasing concentrations of ATP synthase inhibitor oligomycin did not lead to a significant decrease in plasma membrane cholesterol ([S6B Fig](#ppat.1008359.s006){ref-type="supplementary-material"}). Furthermore, cholesterol depletion did not exclusively occur at the plasma membrane during acute treatment with 2-DG, as endosomal cholesterol content decreased by approximately 40% during acute 2-DG treatment ([S6C and S6D Fig](#ppat.1008359.s006){ref-type="supplementary-material"}). Moreover, 2-DG treatment similarly decreased cell surface cholesterol in primary CD4+ T cells, indicating that our results were not isolated to cell lines ([S6E Fig](#ppat.1008359.s006){ref-type="supplementary-material"}).

![Addition of 2-DG sequesters cholesterol from the cell membrane.\
A.) Representative images depicting filipin mean fluorescence intensity per cell indicating two-hour incubation of increasing concentrations of 2-DG decreases surface cholesterol in TZM-bl cells; scale bar 50 μm. B.) Bar charts depicting mean fluorescence intensity per cell of three independent experiments normalised to vehicle in TZM-bl cells (top) and MT4 cells (bottom) in cells treated with 400μg/mL cholesterol, 5mM MBCD and increasing concentrations of 2-DG. C.) Representative images (left) and bar chart (right) of three independent experiments depicting percent of fusion positive cells, as determined by the BlaM assay, relative to vehicle control illustrating increasing concentrations of cholesterol rescues fusion in 2-DG treated TZM-bl cells; scale bar 50 μm. \*p\<0.5, \*\*p\<0.01 \*\*\* p\<0.001 as determined by one-way ANOVA.](ppat.1008359.g004){#ppat.1008359.g004}

To determine if the loss of plasma membrane cholesterol via the inhibition of glycolysis was responsible for the block in virus-cell fusion, we pre-treated our reporter cells with 100mM 2-DG and with increasing concentrations of water-soluble cholesterol to determine if restoration of plasma membrane cholesterol in the face of glycolytic inhibition would restore HIV-1~JR-FL~ fusion in reporter cells. We observed a near-complete rescue of virus fusion when cells were supplemented with 100μg/mL water-soluble cholesterol as reported by the β-lactamase assay ([Fig 4C](#ppat.1008359.g004){ref-type="fig"}). Our results were confirmed by confocal microscopy of β-lactamase-treated cells. Furthermore, acute treatment of primary CD4 T cells cholesterol-lowering drug Simvastatin, a cholesterol synthesis inhibitor, led to the reduction in HIV-1~JR-FL~ fusion ([S3B Fig](#ppat.1008359.s003){ref-type="supplementary-material"}). Ultimately, it appears that the loss of plasma membrane cholesterol and not reduction in ATP upon inhibition of glycolysis negatively impacts HIV-1~JR-FL~ fusion.

Single-cell glycolytic activity influences HIV-1 fusion by affecting membrane order and tension {#sec007}
-----------------------------------------------------------------------------------------------

To assess whether inhibition of glycolytic activity alters the membrane order (i.e. a measurement of membrane packing) in single cells, we utilised a recently established sensor for membrane order, FlipTR \[[@ppat.1008359.ref052]\]. FlipTR, a planarizable, push-pull probe with high photostability \[[@ppat.1008359.ref052],[@ppat.1008359.ref053]\] constructed from two large dithienothiophene flippers, segregates with similar efficiency into different membrane phases \[[@ppat.1008359.ref054]\] and maintains the cell's innate membrane order ([Fig 5A](#ppat.1008359.g005){ref-type="fig"}). We loaded our cells with FliptR and determined the effects of acute glycolysis inhibition on membrane order in TZM-bl cells and compared these effects to cells supplemented with or depleted of cholesterol ([Fig 5B](#ppat.1008359.g005){ref-type="fig"}). The distribution of lifetimes was homogenous throughout the entirety of the cell regardless of cholesterol enrichment or depletion ([Fig 5A and 5B](#ppat.1008359.g005){ref-type="fig"}), indicating that the liquid-ordered and disordered phases are mixed in our spatiotemporal resolution, which has been reported previously in similar time-correlated single photon counting (TCSPC) platforms \[[@ppat.1008359.ref052],[@ppat.1008359.ref055]\]. Treatment with 1mM MBCD showed reductions in lifetime by more than 200ps ([Fig 5B](#ppat.1008359.g005){ref-type="fig"}), indicating a drop in membrane order. Interestingly, cells treated with 2-DG showed similar reductions in membrane order when compared with control cells, supporting that acute 2-DG treatment leads to a loss in high-order lipids in the plasma membrane ([Fig 5B](#ppat.1008359.g005){ref-type="fig"}). These results were confirmed by comparisons of extracted TCSPC histograms. Interestingly, supplementation of 2-DG treated cells with water-soluble cholesterol capable of plasma membrane insertion restored membrane order lifetime values to vehicle-treated values. Notably, increasing membrane tension by subjection to hypo-osmotic shock did not lead to a significant change in the membrane order of the cell.

![Addition of 2-DG decreases cellular plasma membrane order.\
A.) (Left) Cartoon diagram depicting a model of the planarizable, push-pull membrane order probe FlipTR, constructed from two large dithienothiophene flippers, in Ld and Lo environments. (Right) Representative image of FlipTR-stained cells in untreated conditions depicting the homogenous distribution of lifetimes throughout the entirety of the cell; scale bar 25μm. B.) (Top) Representative images of FlipTR-stained cells in listed treatment conditions depicting the extracted τ~m~; scale bar 25μm. (Right) Bar charts depicting the average long lifetime (τ~1~) in TZM-bl cells under listed treatment conditions (n = at least 30 per condition, collected during the course of three independent experiments). \* p\<0.05 \*\* p\<0.01 \*\*\* p\<0.001 as determined by one-way ANOVA.](ppat.1008359.g005){#ppat.1008359.g005}

We utilised a previously published FRET-based reporter of membrane tension, MSS \[[@ppat.1008359.ref056]\], to determine changes in membrane tension of single cells during acute glycolytic inhibition. MSS is an ECFP-YPet FRET-based, membrane-bound tension reporter constructed from an elastic tension-sensing module and two proteins linked with lipid molecules which anchor in raft and non-raft regions of the plasma membrane ([Fig 6A](#ppat.1008359.g006){ref-type="fig"}) \[[@ppat.1008359.ref056]\]. Following the same treatment conditions as those used for the FliptR reporter, we detected a similar pattern in changes in CFP lifetime changes and FRET efficiency (i.e. YPet/ECFP ratio) when compared to vehicle-treated cells ([Fig 6](#ppat.1008359.g006){ref-type="fig"}). Acute cholesterol depletion with mild concentrations of MBCD increased the donor lifetime by more than 100ps (i.e. Δτ = 101ps) ([Fig 6](#ppat.1008359.g006){ref-type="fig"}), indicative of an increase of membrane tension. This result suggests that cholesterol regulates membrane tension in cells. Remarkably, 2-DG treatment led to even larger increases in donor lifetime (i.e. Δτ = 165ps), indicating a reduction in FRET efficiency and an increase distance (i.e. stretch and tension) between donor and acceptor fluorophores ([Fig 6B](#ppat.1008359.g006){ref-type="fig"}). Furthermore, supplementing 2-DG treated cells with water-soluble cholesterol diminished membrane tension values to control levels. None of the treatments altered donor lifetime values of the KMSS probe ([Fig 6B](#ppat.1008359.g006){ref-type="fig"}, right panel), which lacks the Lyn domain necessary for membrane association.

![Acute treatment of TZM-bl cells with 2-DG increases plasma membrane tension.\
A.) (Left) Cartoon diagram model depicting membrane tension FRET probe MSS and its control probe (insensitive to membrane tension), KMSS. (Right) Representative pseudocoloured FRET efficiency (i.e. Ypet/eCFP) images of TZM-bl cells expressing MSS under listed treatment conditions; scale bar 10μm. B.) (Left) Dot plots depicting donor CFP lifetimes of the tension-sensitive MSS probes extracted from single cells in the treatment conditions listed (n = at least 20/condition, collected during the course of three independent experiments; \*p\<0.5, \*\*p\<0.01 \*\*\* p\<0.001 as determined by either one-way ANOVA). (Right) Dot plots depicting donor CFP lifetimes of the tension-insensitive KMSS probes extracted from single cells in the treatment conditions listed (n = at least 30/condition, collected during the course of three independent experiments; \*p\<0.5, \*\*p\<0.01 \*\*\* p\<0.001 as determined by either one-way ANOVA).](ppat.1008359.g006){#ppat.1008359.g006}

Cellular plasma membrane tension is a major regulator of several cellular processes, including those that favour or disfavour virus entry \[[@ppat.1008359.ref021],[@ppat.1008359.ref025],[@ppat.1008359.ref027],[@ppat.1008359.ref057]\]. Since we observed a connection between the glycolytic state of the cell and its corresponding membrane order and tension, we sought to measure how HIV-1~JR-FL~ is impacted by membrane tension during the fusion process. To accomplish this, we analysed single cells transiently expressing the MSS tension reporter during mCherry-Gag-labelled HIV-1~JR-FL~ fusion via single particle tracking concomitant with FLIM of the MSS reporter ([Fig 7A](#ppat.1008359.g007){ref-type="fig"}). Virus fusion was determined by the rapid loss of mCherry signal. Here, in order to assess HIV-1 fusion, we followed mCherry-Gag labelled HIV~JR-FL~ viruses that spectrally complements the MSS donor / acceptor FRET pair (ECFP/YPET). The disappearance of the mCherry-Gag signal for viruses sitting in the plasma membrane (labelled with the MSS biosensor) was employed as a proxy for plasma membrane fusion ([Fig 7B](#ppat.1008359.g007){ref-type="fig"}). We gave up the fourth channel (DiD) as it overlaps with the mCherry signal (both emitting photons in the red region of the spectrum) and employed the signal from the host plasma membrane instead to evaluate membrane tension. Although the average lifetimes for cells expressing MSS probe exposed to HIV particles may recapitulate a common behaviour under different conditions ([Fig 7A](#ppat.1008359.g007){ref-type="fig"}, right panel), we also analysed the standard deviation (SD) of the average lifetimes fluctuation for all pixels (in time and space) for cells expressing the MSS biosensor. Indeed, in a previous report \[[@ppat.1008359.ref058]\]we have shown that rapid FRET-FLIM (acquisitions in the order of 1--5 sec) gives access to evaluate environmental fluctuations and how they affect protein-protein interactions. We endeavoured to evaluate the amplitudes of the fast average lifetime fluctuations in the same way as in our previous work \[[@ppat.1008359.ref058]\] to gather information about the local environment of single HIV particles when engaged with the plasma membrane of the host.

![Multiplexed FLIM with SVT reveals a drop in local tension during single HIV-1 fusion in live cells.\
A.) (Top Left) Cartoon diagram depicting approach to determine plasma membrane tension fluctuations during virus entry. (Top Right) Violin plots of average MSS lifetimes per cell per frame during FLIM acquisition during viral entry in TZM-bl cells. Dots in each plot represent the mean of each condition, which was the calculated from at least 50 frames for at least 20 cells per condition during three independent experiments. (Bottom Left) Standard deviation of MSS lifetimes per cell from real-time FLIM acquisition during viral entry in TZM-bl cells, which was calculated from at least 50 frames for at least 20 cells per condition during three independent experiments. \* p\<0.05 \*\* p\<0.01 \*\*\* p\<0.001 as determined by one-way ANOVA of three independent experiments. (Bottom Right) Representative images of the standard deviation of MSS lifetimes per cell for each condition during viral entry; scale bar 2μm.\* p\<0.05 \*\* p\<0.01 \*\*\* p\<0.001 as determined by one-way ANOVA of three independent experiments. B.) (Top Left) Approach to combine SPT and MSS lifetime values to analyse local membrane tension during HIV-1~JR-FL~ entry. (Right and below) Representative images of a single -mCherry-Gag JR-FL pseudotyped VLP entering MSS-transfected TZM-bl cells are also depicted; scale bar is 20μm and 2μm for the large and smaller images, respectively. (Bottom Left) Representative line-graphs showing local lifetimes in overlapping mCherry-Gag regions (green) and non-overlapping regions (grey) for a single virus particle during entry (loss of mCherry signal, red) in TZM-bl cells. (Bottom Right) Compiled local MSS lifetimes during multiple viral fusion events (green) and respective virus-free regions within the same cell (red) compared to regions of 2-DG treated cells where viruses were incapable of fusion (blue) or rescued events due to cholesterol treatment (purple) in TZM-bl cells. Each point represents a mean of at least 20 cells obtained during three separate experiments.](ppat.1008359.g007){#ppat.1008359.g007}

Interestingly, we initially observed that cells treated with HIV-1~JR-FL~ possessed larger average lifetime fluctuations in CFP donor lifetimes regardless of 2-DG treatment, indicating that cells exposed to virus particles actively undergo changes to membrane tension in response to HIV-1~JR-FL~ ([Fig 7A](#ppat.1008359.g007){ref-type="fig"}, top right panel). These broad fluctuations in membrane tension were Env-dependent, as non-enveloped HIV-1 particles failed to trigger them during SVT acquisition. Pre-treatment of cells with CCR5 HIV-1 entry inhibitors Tak779, a CCR5 antagonist which inhibits co-receptor engagement by HIV-1 gp120, and T20, an HIV-1 fusion inhibitor which competitively binds to gp41 and blocks its post-fusion structure suggested that these changes were CCR5 dependent. Indeed, MSS CFP-donor lifetime fluctuations in Tak779-treated cells were narrowly similar to non-enveloped, naked HIV-1 virions ([Fig 7A](#ppat.1008359.g007){ref-type="fig"}). In contrast, upon T20 treatment, these CFP donor lifetime fluctuations were partially restored, confirming that fluctuations in whole-cell target membrane tension during HIV-1~JR-FL~ entry might be CCR5-dependent. These results were confirmed by analysing the pixel-by-pixel lifetime standard deviations of MSS-containing regions of whole cells during virus entry with and without entry or metabolic inhibitor addition ([Fig 7A](#ppat.1008359.g007){ref-type="fig"}, bottom two panels).

We also evaluated local changes in membrane tension during HIV-1~JR-FL~ entry into individual cells ([Fig 7B](#ppat.1008359.g007){ref-type="fig"}). We tracked the MSS CFP donor lifetime in 3 x 3 pixel regions at the plasma membrane overlapping with mCherry-Gag labelled HIV-1~JR-FL~ during virus approach by multiplexing our FLIM with SVT. Virus fusion was determined by the rapid loss of mCherry-Gag signal. In reporter cells free from any treatment, we noticed a sharp drop in MSS donor lifetimes in plasma membrane regions coinciding with the disappearance of proximal mCherry-Gag signal ([Fig 6B](#ppat.1008359.g006){ref-type="fig"}, bottom left panel, green curve). This sharp decrease in donor lifetime values during viral fusion was not noticeable when analysing the lifetimes of the whole cell ([S7A Fig](#ppat.1008359.s007){ref-type="supplementary-material"}). In comparison, plasma membrane regions lacking virus particles in the same cell did not display any sharp decreases in MSS donor lifetime during virus entry ([Fig 6B](#ppat.1008359.g006){ref-type="fig"}, bottom left panel, grey curve). The local drop in MSS lifetime (i.e. membrane tension) overlapping with mCherry-Gag signal disappearance in space and time was statistically significant when compared to mCherry-Gag signal-free regions of similar size in the same cell ([Fig 7B](#ppat.1008359.g007){ref-type="fig"}, bottom right panel, [S7B Fig](#ppat.1008359.s007){ref-type="supplementary-material"})). However, there was no statistically significant difference in plasma membrane tension values between these two regions at baseline, before loss of mCherry-Gag signal ([Fig 7B](#ppat.1008359.g007){ref-type="fig"}, bottom right panel, Su)). Furthermore, this local drop in MSS CFP donor lifetime was transient, as there was rapid restoration of the MSS CFP donor lifetime almost immediately after the loss of the mCherry-Gag signal ([Fig 7B](#ppat.1008359.g007){ref-type="fig"}, bottom right panel, green curve). In fact, of the total events analysed (n = 20), there was a rebound in MSS CFP donor lifetime values of plasma membrane regions near mCherry-Gag signal that was recently departed compared to baseline MSS lifetime value ([Fig 7B](#ppat.1008359.g007){ref-type="fig"}, bottom right panel, green line; [S7D Fig](#ppat.1008359.s007){ref-type="supplementary-material"})). In some cases, the drop in CFP average lifetimes (increased FRET) occurred with a few seconds delay after mCherry-Gag release ([Fig 7B](#ppat.1008359.g007){ref-type="fig"}, bottom left panel). This drop, however, was recovered before the full release of Gag and right at the moment of fusion pore formation. The drop in local CFP lifetime is recovered before full Gag release ([Fig 7B](#ppat.1008359.g007){ref-type="fig"}). These results indicate that during HIV-1~JR-FL~ entry in reporter cells there is a local reduction in plasma membrane tension that is immediately restored following virus fusion.

When analysing MSS CFP donor lifetimes in 3 x 3 pixel plasma membrane regions overlapping with mCherry-Gag-containing viruses attempting to enter cells treated with 2-DG, we noticed that viruses unable to enter cells were associated with plasma membrane regions with relatively high membrane tension values when compared to vehicle conditions ([Fig 7B](#ppat.1008359.g007){ref-type="fig"}, bottom right panel, blue line). These higher plasma membrane tension values were also present when analysing the whole cell ([S7A Fig](#ppat.1008359.s007){ref-type="supplementary-material"}). Additionally, in 2-DG-treated conditions, we failed to find drops in MSS lifetime values in local PM regions or loss of mCherry-Gag signal ([Fig 7B](#ppat.1008359.g007){ref-type="fig"}, bottom right panel) in all viruses analysed (n = 20), indicating that the localised nature of the plasma membrane tension drop during viral entry is inhibited by 2-DG. Remarkably, we recovered MSS lifetime profile traces similar to non-treated cells when 2-DG-treated cells were supplemented with water-soluble cholesterol ([Fig 7B](#ppat.1008359.g007){ref-type="fig"}, bottom right panel, purple line). Altogether, our results illustrate that a cell's glycolytic activity sets surface cholesterol levels and plasma membrane tension which subsequently determines the success of HIV-1 fusion and thus ultimately HIV-1 infection.

Discussion {#sec008}
==========

Recent studies have stressed the impact of host metabolism on HIV infection \[[@ppat.1008359.ref006],[@ppat.1008359.ref007],[@ppat.1008359.ref013]\]. It has been shown that differences in HIV-1 susceptibility between naive and more differentiated T cells were related to metabolic activity, in particular to oxidative phosphorylation and glycolysis \[[@ppat.1008359.ref013]\]. Inhibition of glycolysis impaired HIV-1 infection in cell culture in all CD4+ T cell types. The mechanism behind these results and the link between metabolism and HIV-1 fusion, however has remained elusive until now. Our data with T cells utilising HIV-1 pseudoparticles corroborates the finding that acute inhibition of glycolysis inhibits productive infection ([Fig 1](#ppat.1008359.g001){ref-type="fig"}). Moreover, we also show that inhibition of glycolysis specifically sequesters cholesterol from the plasma membrane in both T cells and TZM-bl cells ([Fig 4](#ppat.1008359.g004){ref-type="fig"}). The combination of genetically encoded calibrated FRET-based biosensors detecting metabolic activity permitted the use of single-cell ATP/ADP and lactate as an indirect reporter for glycolytic activity (Figs [1](#ppat.1008359.g001){ref-type="fig"} and [2](#ppat.1008359.g002){ref-type="fig"}). These experiments were combined with single cell fusion and infection assays and revealed an important finding: The metabolic landscape predetermined a cell's propensity for HIV-1 infection.

Various envelopes were utilised to pseudotype our HIV-1 particles: VSV-G, HXB2, NL4.3 and JR-FL. It is well-established that VSV-G pseudotyped virions enter host cells via endocytosis \[[@ppat.1008359.ref059]\]. However, the entry site of HIV-1 envelopes are debated and argued to be cell-type dependent \[[@ppat.1008359.ref060]\]. It is thought that HIV-1 R5- and X4-tropic virions enter both primary T cells and T cell lines specifically at the plasma membrane, whereas endocytosis may be dispensable \[[@ppat.1008359.ref061],[@ppat.1008359.ref062]\]. However, in reporter cells, it has been put forth that HIV-1 may productively enter host cells via endosomes \[[@ppat.1008359.ref043]\]. Our report illustrates that in the absence of spinoculation HIV~JRFL~ can fuse in both the plasma membrane and the endosomal compartments. Here, we focused on the events that do occur in the plasma membrane. Importantly, glycolytic activity and the regulation of physical properties in the plasma membrane via cholesterol content seem to be universally required regardless of the entry pathway. Indeed, we detected that this dependence of glycolytic activity and virus entry seemed to be relevant to all pseudotypes analysed (i.e. HIV-1~JR-FL~, HIV-1~NL4.3~, HIV-1~HXB2~ and HIV-1~VSV-G~).

In light of this, the membrane order and tension values obtained from the plasma membrane should be carefully interpreted when extending our discussion of these properties in the context of cholesterol content and virus entry in endosomes. The MSS tension probe was engineered to only label the plasma membrane and our analysis of FlipTR-stained cells was restricted to this region of the cell. Our analysis was restricted to the plasma membrane because FlipTR-labelled endosomes provided insufficient numbers of photons for reliable TCSPC FLIM analysis. Nevertheless, filipin-stained, TZM-bl cells labelled with LDL-Bodipy to identify early endosomes showed reduced cholesterol content in these compartments. These results reflect the fact that the majority of cellular cholesterol resides in the plasma membrane and reductions in plasma membrane cholesterol may be reflected downstream (i.e. in endosomes) \[[@ppat.1008359.ref063]\]. Although further experiments are required to validate the subsequent changes in membrane order and tension upon endosomal cholesterol reduction during 2-DG treatment, given that we have seen reductions in endosomal cholesterol content and VSV-G fusion, it is possible that the membrane properties discussed in the plasma membrane which prevent plasma membrane entry of HIV-1~JR-FL~ could be reflected in the endosomes.

Naïve, primary T cells are known to be exquisitely sensitive to metabolic perturbations, particularly mitochondrial-directed agents such as oligomycin, with even low levels substantially abrogating T cell proliferation and activation \[[@ppat.1008359.ref064]\]. MT4 cells exist as transformed, pre-activated T cells with extraordinarily high glycolytic flux \[[@ppat.1008359.ref065]\]. Similarly to previously reported studies utilizing pre-activated, transformed T cells \[[@ppat.1008359.ref065]\], such as Jurkat and CEM cell lines, the treatment of MT4 cells with mitochondrial-directed agents (i.e. oligomycin) often fails to alter intracellular ATP pools, where treated cells remain energetically competent. Similarly, we illustrated that oligomycin treatment failed to not only alter the redox ratio as determined by two-photon microscopy ([S2 Fig](#ppat.1008359.s002){ref-type="supplementary-material"}) but failed to alter the success of HIV-1 infection ([Fig 1B](#ppat.1008359.g001){ref-type="fig"}). These findings, contextualised by prior studies, emphasize the importance of glycolytic flux and HIV-1 infection. Indeed, naïve T cells, heavily reliant on oxidative phosphorylation, are highly resistant to HIV-1 infection. However, differentiated T cell subsets are not only more less reliant oxidative phosphorylation as they become more glycolytically dependent, but are increasingly susceptible to HIV-1 infection \[[@ppat.1008359.ref013],[@ppat.1008359.ref066]\]. Our study therefore adds to the discussion of how metabolism may influence HIV-1 infection at the level of entry. However, considering the fact our study solely scrutinized the role of glycolytic flux in the context of viral fusion, other metabolites which modulate immune function and differentiation (e.g. glutamine) should be explored. Indeed, metabolites such as glutamine are paramount for T cell differentiation and therefore likely play an important role for HIV-1 susceptibility.

Plasma membrane lipid bilayers contain a variety of lipids which are thought to be laterally segregated into domains to regulate fusion, endocytosis and signal transduction \[[@ppat.1008359.ref067],[@ppat.1008359.ref068]\]. Lo domains are thought to be dominated by saturated lipids (i.e. sphingolipids) and sterols (i.e. cholesterol) surrounded by a pool of unsaturated phospholipids constituting Ld domains. The contributions of cholesterol and the boundaries between Lo and Ld domains to the successful entry of viruses including HIV-1 are well-established. Membrane order and tension are significant contributors to several membrane-regulated processes in human cells important for viral infection, including viral entry (i.e. fusion and endocytosis) and egress \[[@ppat.1008359.ref024],[@ppat.1008359.ref025]\]. Recently, several studies have offered a link between metabolic activity and sensing in live cells to cellular membrane tension indicating that various membrane-regulated processes are controlled by master metabolic sentinels \[[@ppat.1008359.ref069]--[@ppat.1008359.ref071]\]. Our results further build upon this link suggesting that high glycolytic activity may increase susceptibility of cells to support HIV-1 entry due to membrane tension regulation.

Specifically, our observation that decreased virus entry occurs following glycolytic inhibition could be linked to alterations in either membrane order or tension. We hypothesise that glycolysis directly, through the production of acetyl-CoA precursors, or indirectly regulates cholesterol in cellular membranes as the addition of 2-DG inhibited cholesterol accumulation without affecting CD4 or co-receptor expression levels ([S4 Fig](#ppat.1008359.s004){ref-type="supplementary-material"}). This loss in cholesterol led to drastic increases in membrane tension and loss of membrane order, owing to the sequestration of cholesterol from the plasma membrane ([Fig 5](#ppat.1008359.g005){ref-type="fig"} and [S7 Fig](#ppat.1008359.s007){ref-type="supplementary-material"}). These two aspects are crucial for the HIV-1 fusion reaction for many reasons. First, it has been shown that lipid-ordered (i.e. cholesterol-laden) and lipid-disordered membrane domains (also termed raft boundaries) can act as an attractor for HIV Env \[[@ppat.1008359.ref029],[@ppat.1008359.ref072]\]. Both experimental and theoretical studies show that the presence of raft boundaries in the vicinity of HIV-1 entry sites reduces the energy barrier required to perform virus-cell fusion \[[@ppat.1008359.ref021]\]. Moreover, the line tension created at lipid domain boundaries drives gp41-mediated fusion, owing to the mismatches in lipid length occurring at Lo and Ld boundaries, most likely creating membrane curvature which favours virion fusion \[[@ppat.1008359.ref021]\] ([Fig 8](#ppat.1008359.g008){ref-type="fig"}). Cholesterol and other ordered lipids are known to maintain negative spontaneous curved membrane domains, which facilitates the creation of a fusion stalk by reducing its formation energy in addition to enabling its progression to fusion pore formation \[[@ppat.1008359.ref073]\]. The sequestration of cholesterol from the host membrane in glycolytically-inactivated cells arrests HIV fusion, as this line-tension necessary to drive fusion is diminished. Furthermore, sequestration of cholesterol from the host plasma membrane ostensibly increases membrane tension ([Fig 8](#ppat.1008359.g008){ref-type="fig"}), which has been illustrated previously to collapse hemifusion intermediates \[[@ppat.1008359.ref074]\] in addition to preventing the formation of highly curved intermediates, disfavouring packing defect formation and the generation of nucleation points for two membranes to be joined \[[@ppat.1008359.ref073]\]. Moreover, this increase in membrane tension might in turn have an effect on the optimal hydrophobic equilibrium between ordered and disordered lipid domains needed to complete the fusion reaction \[[@ppat.1008359.ref021],[@ppat.1008359.ref029]\].

![Cholesterol availability regulates the transition between HIV-1 hemifusion and fusion.\
HIV-1 Env sequentially interacts with CD4 and CCR5 at the boundaries of ordered lipid domains. The progression toward hemifusion is not cholesterol dependent as cells treated with 2DG had a reduced concentration of cholesterol and were able to progress toward HIV-1 hemifusion. Viruses exposed to cells pre-treated with 2DG were arrested right at hemifusion and only the addition of cholesterol rescued full fusion suggesting that cholesterol is a limiting factor in the HIV-1 fusion reaction in the process of fusion pore formation. White circles (left panels) represent lipid boundaries where cholesterol might induce HIV-1 Env priming and favour the pre-hairpin intermediate. Red circles (right panels) represent a potential role of cholesterol during fusion pore formation and membrane curvature.](ppat.1008359.g008){#ppat.1008359.g008}

It is quite possible that glycolytic activity may be related to the availability of other lipids on the plasma membrane that could be essential for HIV-1 entry, in addition to other viruses. Indeed, phospholipid biosynthesis is linked to glycolysis via dihydroxyacetone phosphate, formed from glycerol-3-phosphate via its reduction by NADH. Furthermore, it is known that certain phospholipids act to enhance HIV-1 entry, and that chemically-modified phospholipids alter the curvature of the membrane, which can modify virus entry \[[@ppat.1008359.ref075]\]. Future experiments should investigate whether glycolytic activity alters the availability of other phospholipids known to enhance HIV-1 entry.

We hypothesise that there is a range of hydrophobic mismatch between ordered and disordered lipid domains that renders HIV fusion plausible. When this equilibrium is lost (both toward high or low tension) the energy required for gp41 fusion peptide to complete fusion (expressed in tens of kBT, \[[@ppat.1008359.ref021]\]) is not compatible with the completion of the fusion reaction. This is why depletion of cholesterol might allow HIV Env to be primed with CD4 and CCR5 followed by arrest at hemifusion ([Fig 3](#ppat.1008359.g003){ref-type="fig"}) even if overall tension in the host cell membrane is increased ([Fig 8](#ppat.1008359.g008){ref-type="fig"}). Moreover, our data suggests that cholesterol is a limiting factor for the transition between HIV-1 hemifusion and fusion ([Fig 8](#ppat.1008359.g008){ref-type="fig"}) and not necessarily during the sequential interactions between HIV-1 Env with CD4 and CCR5 co-receptor at phase boundaries \[[@ppat.1008359.ref029]\]. Indeed, in cells treated with 2DG where cholesterol is sequestered, HIV-1 was able to progress until hemifusion. The external addition of cholesterol allowed full fusion to be completed ([Fig 7](#ppat.1008359.g007){ref-type="fig"}).

Our results indicate that glycolytic activity is needed to maintain higher lipid order and lower levels of membrane tension inside cells, two characteristics that promote HIV-1 fusion with cells. Furthermore, we have also shown that HIV-1 induces broad fluctuations in host global membrane tension during virus entry, yet require localised, transient reductions in plasma membrane tension in order to enter their host cell. Moreover, our results with primary cells ([S3](#ppat.1008359.s003){ref-type="supplementary-material"} and [S6](#ppat.1008359.s006){ref-type="supplementary-material"} Figs) reinforce our claims that host cell glycolysis regulates cholesterol availability and HIV-1 entry. In brief, we demonstrated that treatment of primary CD4+ T cells with 2-DG led to similar decreases in HIV-1~HXB2~ entry and that treatment with cholesterol-lowering medication (i.e. simvastatin) recapitulated this result ([S3 Fig](#ppat.1008359.s003){ref-type="supplementary-material"}). Furthermore, 2-DG treatment led to similar cell surface cholesterol reductions ([S6 Fig](#ppat.1008359.s006){ref-type="supplementary-material"}). Ultimately, our work shows that glycolytic inhibition with 2-DG creates changes in global and local membrane tension that restricts HIV-1 fusion at the hemifusion stage and that this inhibition can be tied to cholesterol availability.

Material and methods {#sec009}
====================

Cell culture {#sec010}
------------

TZM-bl (already existing collection from Quentin Sattentau lab) and Lenti-X-293T (Takara Bio, Europe, France) cells were cultured in either complete Dulbecco's Modified Eagle Medium (DMEM) or DMEM F-12 (Life Technologies), respectively, both of which contained 10% fetal bovine serum (FBS), 1% Penicillin-Streptomycin (PS) and 1% L-glutamine (LGlut). Cells were maintained at 37°C which provided 5% CO~2~. MT4 cells (already existing collection from Alex Compton lab) were cultured in RPMI containing 10% FBS, 1% PS and 1% L-Glut.

CD4 T cell lymphoblasts were generated from human peripheral blood CD4 T cells isolated from healthy donors (Levine et al., 1997). Briefly, CD4 T cells were isolated by negative selection (RosetteSep Human CD4^+^ T cell Enrichment Kit, StemCell technologies) following the manufacturer's procedure. When referring to rested CD4 T cells, these T cells are kept overnight in complete medium (RPMI 1640 media supplemented with 10% heat-inactivated fetal bovine serum, 50 U/ml of Penicillin-Streptomycin, 2 mM L-Glutamine, 10 mM HEPES, 1 mM Sodium Pyruvate, and 100 μM non-essential amino acids) prior to experimental use. In any other case, CD4 T cells were activated for 2 days using anti-CD3/anti-CD28 T-cell activation and expansion beads (Dynabeads, ThermoFisher Scientific) in complete medium supplemented with 100 U/ml of recombinant human IL-2 (PeproTech). After 2 days, T cells are separated from beads and incubated for 3 days in fresh IL2-containing medium at a concentration of 1 × 10^6^ cells/ml prior to experimental use.

Reagents and antibodies {#sec011}
-----------------------

All chemical and biochemical reagents were obtained from the following sources: The Flipper-TR probe was purchased from Spirochrome (Geneva, Switzerland). Antibodies against CD4 conjugated to PercP Cy5.5 (ab161a1) and CCR5 conjugated to FITC (ab11466) were from BioLegend (San Diego, CA, USA) and Abcam (Cambridge, UK), respectively. β-lactamase CCF2-AM loading solutions from the LiveBLAzer FRET B/G Loading Kit was obtained from Life Technologies (Carlsbad, CA, USA); Filipin, 2-deoxy-glucose (2-DG), Methyl-β-cyclodextrin (MBCD) and water-soluble cholesterol \[[@ppat.1008359.ref076]\] was obtained from Sigma-Aldrich (St. Louis, MO, USA). Low density lipoprotein (LDL) from human plasma (BODIPY) complex and Simvastatin were obtained from ThermoFisher.

Plasmids transfections {#sec012}
----------------------

The pR8ΔEnv plasmid (encoding HIV-1 genome harbouring a deletion within Env), pcRev, VPR-BlaM, Gag-eGFP and VSV-G were kindly provided by Greg Melikyan (Emory University). The plasmid encoding the JR-FL envelope protein was a kind gift from James Binley (Torrey Pines Institute for Molecular Studies). The MSS sensor was kindly provided from Bo Liu (Dalian University of Technology). Perceval and Laconic plasmids were obtained from Addgene. Transient transfections of Perceval, Laconic (Addgene plasmid numbers 21737 and 44238, respectively) and the MSS probe was performed according to the manufacturer's protocol for GeneJuice (Novagen). Transiently-transfected cells were analysed by FLIM 24--48 hours later.

Virus production {#sec013}
----------------

Vpr-BlaM-containing, JR-FL and VSV-G pseudotyped viral particles were produced via transfection of 60--70% confluent Lenti-X-HEK-293T cells seeded in T175 flasks. Component DNA plasmids were transfected into Lenti-X-HEK-293T cells via GeneJuice (Novagen) according to manufacturer's protocol. Specifically, cells were transfected with 2 μg pR8ΔEnv, 1 μg pcREV, 3 μg of the appropriate viral envelope (either VSV-G, the CCR5-tropic HIV-1 strain JR-FL, or the CXCR4-tropic HIV-1 strain NL4.3), and either 2 μg Vpr-BlaM if to be used for β-lactamase assays, or 3μg of eGFP-GagΔEnv if being used for flow cytometry experiments. Alternatively, if to be utilised for single particle tracking, 2 μg pR8ΔEnv, 3 μg Gag-eGFP-Δenv, 1 μg pcREV and 3 μg of the appropriate viral envelope were transfected into HEK-293T cells. If to be utilised for single particle tracking whilst recording MSS FLIM lifetime acquisition, 2 μg pR8ΔEnv, 2 μg mCherry-2xCL-YFP-Vpr, 1 μg pcREV and 3 μg of the appropriate viral envelope. All transfection mixtures were then added to cells supplemented in complete DMEM F12, upon which time they were incubated in a 37 °C, 5% CO~2~ incubator. 12 hours post-transfection, the medium was replaced with fresh, phenol-red free, complete DMEM F12 after washing with PBS. Cells were subsequently incubated for a further 24 hrs. If viruses were to be utilised for single particle tracking, 12 hours post-transfection, the transfection mixture was removed and cells were washed twice with PBS before being incubated at 37º C with DMEM F12 medium containing 10μM DiD (Life Technologies) for 4 hour. The staining mixture was subsequently removed, upon which time the cells were washed twice with PBS and DMEM F12 was then added again and incubated for an additional 24 hours prior to harvesting as follows. 48 hrs post-transfection for either Vpr-BlaM, double-labelled or immature virions, the supernatant containing virus particles was harvested, filtered with a 0.45 μm syringe filter (Sartorius Stedim Biotech), aliquoted and stored at −80 °C.

Virus titering {#sec014}
--------------

To titer the produced pseudovirions, 2 x 10^4^ TZM-bl cells were seeded in complete DMEM, in triplicate, in a 96-well plate (Falcon) and allowed to grow in a 37 °C, 5% CO~2~ incubator for 24 hours. Subsequently, the media was removed and replaced with 10-fold serially-dilutions of the produced pseudovirus particles. Aliquoted Vpr-BlaM-containing or double-labelled JR-FL and VSV-G pseudotyped viral particles additionally contained the β-galactosidase gene in the pr8ΔEnv construct. Cells were incubated for an additional 48 hours in a 37 °C, 5% CO~2~ incubator, upon which time the medium was removed, the cells were then washed with PBS and fixed with 2% paraformaldehyde for 10 minutes. After an additional PBS wash post-fixation, an X-gal (i.e. BCIG, or 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) solution comprised of 500mM K~3~\[Fe(CN)~6~\], 250mM K~4~\[Fe(CN)~6~\], 1M MgCl~2~, PBS, and 50mg/mL Xgal was added with to the cells and incubated for two hours at 37 °C, 5% CO~2~ incubator in the dark. Afterwards, cells were washed with PBS and subsequently imaged with a 630nm excitation continuous laser (Leica, Manheim) while recording the emission spectra with a 650-750nm emission window, pixel by pixel (512 x 512) using a Leica SP8 X-SMD microscope with a lambda resolution of 12 nm, in order to count infection-positive cells for each 10-fold dilution to extrapolate the virus titer.

Single virus tracking: Spun vs non-spun cells {#sec015}
---------------------------------------------

HIV pseudoviruses decorated with JRFL Env and labelled with DiD in the membrane and Gag-GFP were exposed on the top of TZM-bl cells at 4°C. These cells were either spun for 30 min at 2100 G in a refrigerated centrifuge, or left 30 min in the cold so that the HIV particles would sediment down on the surface of the TZM-bl cells. In both cases the particles that were pullulating around and not primed were washed out with cold PBS. The observation chambers were then put under the microscope set at 37°C and the cold medium immediately replaced by warm medium set at 37°C right at the moment when we started the HIV fusion reaction and the imaging acquisition procedure. We employed the SP8 X SMD confocal microscope described also below. Briefly a white laser (Leica, Germany) and an Argon laser were combined (633nm and 488nm) employing a 63X 1.4 NA objective to excite DiD and Gag-GFP respectively alternating lines to avoid emission bleed-through. The emission photons for both fluorescent signals were detected using HyD photon counting detectors. A third detector (PMT) was also used to recover the transmission light simultaneously.

β-lactamase assay {#sec016}
-----------------

Four-hours post-addition of the pseudotyped virus particles harbouring Vpr-BlaM at the specified MOI to the transfected TZM-bl cells, virus particles were removed, and cells were washed twice with PBS. After the washes, complete DMEM was added to each well and the cells were allowed to incubate at 37°C, 5% CO~2~. Cells were then loaded with CCF2-AM from the LiveBLAzer FRET---B/G Loading Kit (Life Technologies) and incubated at room temperature in the dark for 2 hrs. After this incubation step, the CCF2 was removed, and cells were washed with PBS and maintained in 2% FBS-containing, phenol-red free DMEM prior to imaging.

β-lactamase assay spectral analysis {#sec017}
-----------------------------------

CCF2-loaded TZM-bl or primary rested CD4+ T cells were excited with a 405nm continuous laser (Leica, Manheim) while recording the emission spectra with a 430-560nm window, pixel by pixel (512 x 512) using a Leica SP8 X-SMD microscope with a lambda resolution of 12 nm. Utilising ImageJ (<http://imagej.nih.gov/ij/>), the ratio of the blue (440-480nm, cleaved CCF2) to green (500-540nm, uncleaved CCF2) emission was calculated pixel-by-pixel using 20X objective. Statistical analyses of the BlaM data were performed using a two-tailed Fishers Exact Test (SigmaPlot, San Jose, CA). Cells were then removed of the CCF2 mixture and allowed to incubate for 24 hours in complete DMEM if they were to be analysed for infection by the B-Gal assay (below) for infection.

β-galactosidase assay {#sec018}
---------------------

After imaging the CCF2-loaded TZM-bl cells, cells were washed with PBS and maintained in 2% FBS-containing, phenol-red free DMEM overnight for 12 hours in a 37 °C, 5% CO~2~ incubator. At least 36 hours after the addition of the pseudotyped virus particles, the medium was removed, and the cells were then washed with PBS and subsequently fixed with 2% paraformaldehyde for 10 minutes. After an additional PBS wash post-fixation, an X-gal (i.e. BCIG, or 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) solution comprised of 500mM K~3~\[Fe(CN)~6~\], 250mM K~4~\[Fe(CN)~6~\], 1M MgCl~2~, PBS, and 50mg/mL Xgal was added to the cells, upon which time the cells were incubated for two hours in a 37 °C, 5% CO~2~ incubator in the dark. Afterwards, cells were washed with PBS and subsequently imaged with a 630nm excitation continuous laser (Leica, Manheim) while recording the emission spectra with a 650-750nm emission window, pixel by pixel (512 x 512) using a Leica SP8 X-SMD microscope with a lambda resolution of 12 nm, in order to identify infection-positive cells.

Filipin immunofluorescence staining {#sec019}
-----------------------------------

TZM-bl cells, MT4 cells or PBMCs were treated with either a vehicle control, MBCD, water-soluble cholesterol or various concentrations of 2-DG for 2 hours were fixed with 4% PFA for 15 minutes at room temperature on Ibidi 35mm gridded dishes. The fixative was washed away three times with cold PBS and then quenched with 1.5mg/mL glycine for 10 minutes at room temperature. Cells were then stained with filipin at 50μg/mL for 2 hours at room temperature, protected from light. The filipin stain was washed away three times with PBS and then cells were subsequently imaged using a SP8--X-SMD microscope with the FALCON module from Leica Microsystems (Manheim, Germany). If cells were to be analysed for endosomal filipin content, cells were loaded with LDL-Bodipy at a concentration of 10 μg/mL and allowed to incubate at 37 °C, 5% CO~2~ for 2 hours. The LDL-Bodipy complex was then removed, cells were washed three times with room temperature DPBS. Following washing, cells were then treated with specified treatment conditions as described (e.g. vehicle or 2-DG treatment). After treatment, cells were fixed and stained with filipin and imaged as described above. Z-stacks were acquired with a step-size of 0.3 μm for colocalization studies of the median 5--10 slices in each stack for each image of each condition.

Fluorescence lifetime imaging microscopy (FLIM) {#sec020}
-----------------------------------------------

Live TZM-bl cells expressing Perceval, Laconic or FlipTR were imaged using a SP8--X-SMD Leica microscope, whilst MSS-expressing cells were imaged using a SP8--X-SMD microscope with the FALCON module, both from Leica Microsystems (Manheim, Germany). Cells of interest were selected under either a 20x air-immersion or 63x oil-immersion objective (i.e. Perceval, Laconic and FlipTR) or a 100x/1.4 oil immersion objective (i.e. MSS). Perceval-expressing cells were excited using a 488 nm pulsed laser, Laconic-expressing cells were excited using a 470 nm pulsed laser, both tuned at 40 MHz coupled with single photon counting electronics (PicoHarp 300) and subsequently detected by hybrid external detectors in photon counting mode. FlipTR stained cells were excited with a 488 nm puled laser tuned at 20MHz.

MSS-expressing cells were subjected to a 440nm picosecond pulsed diode laser PDL 800-B (PicoQuant) tuned at 40MHz in order to excite the FRET donor (CFP) while the emitted photons passing through the 450-480nm emission filter were detected using the internal hybrid detector in photon counting mode. Time-domain FLIM experiments were performed using a TCSPC approach operated by the FALCON module (Leica Microsystems, Manheim, Germany) integrated within the Leica SP8-X-SMD microscope.

In order to remove artefacts caused by noise or photo--bleaching and insufficient signal to noise, cells with negligible amounts of bleaching and at least 250--1000 photons per pixel were only allowed in the analysis. Symphotime 64 software (Picoquant) was utilized to acquire the fluorescence decay of each pixel in individual cells expressing Perceval, Laconic, or Flipper-TR-stained cells, which was deconvoluted with the instrument response function (IRF) and fitted by a Marquandt nonlinear least--square algorithm with two--exponential models. The mean fluorescence lifetime (τ) was calculated as previously described using Symphotime. Statistical analysis of the lifetime data was performed using a two-tailed t-test (Origin, Northhampton, MA, USA).

Label free NADP(H) two photon FLIM {#sec021}
----------------------------------

A two photon FLIM SP8 DEEP DIVE FALCON microscope (Leica Microsystems, Mannheim, Germany) equipped with 3 non-descanned photon counting detectors was employed to measure the autofluorescence of NAD(P)H in live cells (both MT4 T cells and TZM-bl cells) as explained in \[[@ppat.1008359.ref077]\]. Briefly, the two-photon laser was tuned at 730 nm and the emission window was set at 450--500 nm. A 100X 1.4 NA corrected for IR was employed to recover all images. Images were collected so that at least 100--1000 photons per pixel were acquired after 3--5 min. A two exponential analysis fitting pixel-by-pixel the fluorescence decay from all pixels in all images was performed (FALCON Leica software, Germany) to recover the ratio of protonated and non-protonated NAD(P)H. Regions of interest comprising individual cells treated with and without 2-DG gave different ratios as shown in [S2 Fig](#ppat.1008359.s002){ref-type="supplementary-material"}. Phasor plots \[[@ppat.1008359.ref078]\]were employed to show the shift in NADP(H) concentration when comparing cells (both TZM-bl and MT4) in either vehicle or 2-DG-treated conditions. Leica software (LASX) was employed to produce the phasor plots (Leica Microsystems, Mannheim, Germany).

Flow cytometry {#sec022}
--------------

Single-round infections were performed either with HIV-1~VSV-G~-eGFP-Gag or HIV-1~NL4.3~-eGFP-Gag. MT4 T cells were infected in triplicate (1 x 10^5^ cells/ well, 200uL) at an MOI of 1. Active HIV-1 infection was estimated by flow cytometry (BD LSRII, BD bioscience) as the percentage of eGFP-expressing, live MT4 T cells 48 hours after infection, and live cells were determined via LIVE/DEAD Fixable Near-IR Dead cell stain for 633/635 nm to stain dead cells following manufacturer's instructions (Invitrogen).

Extrapolating the ATP:ADP ratio and relative lactate concentrations and MSS lifetimes {#sec023}
-------------------------------------------------------------------------------------

Utilizing Symphotime software (Picoquant Gmbh, Berlin, Germany), each whole cell expressing Perceval or Laconic was determined to be a region of interest. The region of interest with the smallest lifetime (τ~int~) was selected as the cell with the highest amount of ATP relative to ADP in the field of view analysed. From this region of interest, the short lifetime component (τ~1~) was fixed in all other analysed cells when acquiring the TCSPC fluorescence decay of each pixel, as this component possessed the highest amplitude *a*~*1*,~ therefore representing the relative ATP concentration in the cell. The lifetime component τ~2~ was interpreted to represent the relative contribution from ADP binding to the Perceval sensor, and therefore its corresponding amplitude *a*~*2*~ was utilized to extract the relative ADP concentration. The resulting two-exponential decay, which was deconvoluted with the instrument response function (IRF) and fitted by a Marquandt nonlinear least--square algorithm contained two amplitudes, *a*~*1*~ and *a*~*2*~. The ratio (i.e. *a*~*1*~*/a*~*2*~*)* of these two amplitudes was taken to generate the ATP:ADP ratio. To extract the relative lactate concentration from Laconic, a similar approach was utilised, where the amplitude *a*~*1*~ of the long lifetime component τ~1~ was divided by the sum of the amplitudes from the two-component exponential decay.

For the MSS probe, we utilised the internal FALCON module Leica Microsystems, Manheim, Germany) integrated within the Leica SP8-X-SMD microscope for our FLIM analysis. Whole cells expressing the MSS probe or 3 x 3 pixel-by-pixel regions of the MSS-labelled membrane overlapping with mCherry-labelled virions were chosen as our region of interest. To increase photon counts per pixel, we binned 5 x 5 pixels in addition to grouping frames of our acquisition in groups of 10. We utilised a three-exponential decay deconvoluted with the IRF and fitted by a Marquandt nonlinear least-square algorithm containing three amplitudes with the third long lifetime component fixed to the average of all cells analysed to isolate short τ~1~ and long τ~2~. The longer lifetime component (τ~2~) was chosen to represent the donor lifetime and therefore the membrane tension. When analysing 3 x 3 pixel-by-pixel regions of the MSS-labelled membrane overlapping with mCherry-labelled virions, to accommodate for low photon counting numbers, we utilised a single-exponential decay to extract MSS τ.

Statistics {#sec024}
----------

All statistical calculations (t-test, ANOVA, standard deviation and error) were calculated using Originlab software (Northhampton, USA)

Supporting information {#sec025}
======================

###### Acute 2-deoxyglucose treatment abrogates HIV-1~NL4.3~ infection in MT4 cells and induces fluorescent lifetime changes in biosensors Laconic and Perceval.

A.). Bar charts depicting % eGFP-expressing cells as a marker of infection illustrating that acute treatment with increasing concentrations of 2-DG led to reductions in HIV-1~NL4.3~ infection in human MT4 T cells. B.) Representative intensity (left) and fluorescent lifetime imaging (right) of single cells transiently expressing intracellular lactate biosensor Laconic in single TZM-bl cells with increasing concentrations of glycolytic inhibitor 2-DG; scale bar, 50μm. C.) Representative intensity (left) and fluorescent lifetime imaging (right) of single cells transiently expressing intracellular ATP:ADP ratio biosensor Perceval in single TZM-bl cells with increasing concentrations of glycolytic inhibitor 2-DG; scale bar, 50μm. D.) Dot plots representing lifetimes of intracellular lactate biosensor Laconic extracted from live, single cells as regions of interest post-treatment for 2-hours with increasing concentrations of 2-DG in TZM-bl cells. E.) Dot plots representing lifetimes of intracellular ATP:ADP ratio biosensor Perceval extracted from live, single cells as regions of interest post-treatment for 2 hours with increasing concentrations of 2-DG in TZM-bl cells.

(TIF)

###### 

Click here for additional data file.

###### Acute treatment of 2-deoxyglucose, not oligomycin, inhibits glycolytic flux in a pH-independent manner cell lines.

A.) Representative images (left) and phasor plots (right) representative of FLIM distributions of NAD(P)H alone (top row), vehicle-treated conditions in TZM-bl (left) and MT4 cells (right) (middle row) and acute treatment with 2-DG (bottom row); scale bar 5 μm. Phasor FLIM plots illustrate each pixel converted via Fourier Transform to the phase domain. The phasor plots illustrate longer lifetimes (i.e. enzyme-bound NAD(P)H, lower glycolytic flux) to the left and shorter lifetimes (free NAD(P)H, higher glycolytic flux) to the right. B.) Bar charts representing the lifetime extracted from single TZM-bl cells expressing intracellular pH biosensor pHRed indicating a lack of change in fluorescence lifetime during acute 2-DG treatment. C.) Box plot representing the ratio of NAD(P)H~free~ vs. NAD(P)H~protein-bound~ in MT4 cells treated with oligomycin. D.) Box plot representing the ratio of NAD(P)H~free~ vs. NAD(P)H~protein-bound~ in MT4 cells treated with 2-DG. The presented two-photon FLIM data was acquired as described in material and methods. Box plots represent data acquired from at least 30 cells per condition acquired from three independent experiments.\*\*\* p\<0.001 as determined by one-way student's T-test.

(TIF)

###### 

Click here for additional data file.

###### Acute treatment with 2-DG or simvastatin abrogates HIV-1~HXB2~ fusion in primary CD4+ T cells.

A\) Primary cells were exposed to either naked (i.e. No Env) HIV-1 or HIV-1~HXB2~ virions and treated with vehicle, 100 mM 2-DG or 10μM Simvastatin. Brightfield images (first row) show that in all cases the integrity of the cells was maintained. The BlaM assay for HIV fusion (Blue/Green channel ratio images, second row) shows that the number of positive fusion cells (red) is higher for cells only exposed to HIV~HXB2~. Cells exposed to both HIV~HXB2~ and 100 mM 2-DG or 10uM Simvastatin were less susceptible to HIV~HXB2~ fusion as limited fusion positive cells (red cells) were detected. The pixel-by-pixel histograms for each condition are also shown for each condition in the lowest row. B) When quantifying the overall populations of cells (i.e. at least100 cells per condition) and taking as a negative control No Env HIV~HXB2~ (gray dots, and straight gray line) as a threshold for fusion, one could see that in the green channel versus blue channel plots (based in average intensities recorded from single cells) 10.1% of primary T cells were fusion positive when exposed to HIV~HXB2~ (red dots above the grey No Env threshold line in the left panel). For cells treated with 100 mM 2-DG, only 2.2% turned out to be fusion positive (red dots above the grey line in the middle panel). In turn, for cells treated with 10μM Simvastatin, only 2.4% were fusion positive (green dots above the grey No Env threshold line, right panel).

(TIF)

###### 

Click here for additional data file.

###### Acute treatment with 2-DG does not alter cell viability or cell-surface receptor expression, and single virus tracking of HIV-1~JR-FL~ in vehicle or 2-DG-treated conditions.

A.) Bar charts depicting the percentage of dead TZM-bl cells detected by propidium iodide (PI) staining in single cells treated with increasing concentrations of 2-DG for two hours. B.) Bar charts representing normalized HIV-1~JR-FL~ fusion relative to vehicle in single TZM-bl cells as determined by the β-lactamase assay in cells treated with glucose-free medium for two hours before virus addition. C.) Bar charts illustrating that relative CD4 and CCR5 expression levels do not drastically change during listed treatment conditions. Bar charts shown in the panel are representative of a mean of three independent experiments. D.) Representative fluorescence series of images (left) and single particle tracking traces (right) of Gag-eGFP (green) and DiD (red) dual-label HIV-1~JR-FL~ pseudovirions in TZM-bl cells (scale bar) illustrating that in control conditions (i.e. no 2-DG) that HIV-1~JR-FL~ entry in TZM-bl cells proceeds with a precipitous loss of Gag-eGFP and maintenance of DiD signal, indicative of endocytosis as previously described (n = 15, acquired during three independent experiments). E.) Representative fluorescence series of images (left) and single particle tracking traces (right) of Gag-eGFP (green) and DiD (red) dual-label HIV-1~JR-FL~ pseudovirions in TZM-bl cells (scale bar) illustrating that in 2-DG-treated conditions (i.e. 100mM 2-DG) that HIV-1~JR-FL~ entry in TZM-bl cells may also proceed with a slow decay of DiD signal and maintenance of eGFP-Gag signal, indicative of hemifusion (n = 15, acquired during three independent experiments). \*p\<0.5, \*\*p\<0.01 \*\*\* p\<0.001 as determined by either one-way ANOVA or one-way student's T-test.

(TIF)

###### 

Click here for additional data file.

###### Single virus tracking of HIV-1~JR-FL~ viruses comparing spun vs. non-spun TZM-bl cells.

A.) HIVJR-FL pseudoviruses labelled with DiD and Gag-GFP exposed on TZM-bl at 4°C during 30 min as described in material and methods were placed under the microscope at 37°C to start the entry process. White dotted circles indicate the HIV-1 particles co-labelled with both colours (red for DiD and green for Gag-GFP). A subset of these particles are only labelled with either Gag-GFP (green dots) or DiD (red dots). These particles were ignored. Scale Bar = 10 μm B.) Three regions of interest showing: i) endosomal fusion (first row, where a yellow particle turns red signifying DiD redistribution within the endosomal compartment and Gag-GFP release); ii) plasma membrane (PM) fusion (second row, where a double labelled particle designated with an arrow first changes from yellow to green indicating hemifusion (i.e. DiD dilution on the PM) and then Gag-GFP disappearance. A white dotted particle undergoing endosomal fusion is also shown indicating that the focus was kept stable during the acquisition and also that both phenomena can occur in non-spinoculated cells simultaneously. The third row shows a particle undergoing hemifusion (unable to progress toward full fusion as the GFP-Gag remains through time). Scale bar = 1 μm C.) Left panel: The statistics for spun (dark green) versus non-spun (light green) cells are shown. The proportion of events (0 to 1) for endosomal fusion, hemifusion, colour separation (capsid release) and plasma membrane fusion are shown for a total of n = 137 and n = 56 double labelled particles for spun and non-spun TZM-bl cells respectively. Also, a small fraction of events for both spun and not-spun conditions showed colour separation; colour separation is defined as double-labelled (yellow viruses) internalized within endosomes (labeled with DiD and Gag-GFP) undergoing fusion. Right at the moment of fusion DiD redistributes around the endosomal membrane and partially uncleaved Gag-GFP is released into the cytosol.The right panel depicts the cumulative distribution kinetics for HIV-1 particles undergoing: i) Fusion for spun cells (solid green dots); ii) hemifusion for non-spun cells (solid red dots), iii) full endosomal fusion for spun cells (open red dots) and iv) plasma membrane fusion non-spun cells (open green dots).

(TIF)

###### 

Click here for additional data file.

###### Acute treatment with 2-DG leads to cell surface cholesterol reduction in cell lines and primary cells in addition to the endosomal compartment.

A.) Bar charts depicting normalized filipin mean fluorescence intensity per cell in various treatment conditions listed to illustrate that 2-DG treated cells have plasma membrane cholesterol content similar to 1mM MBCD-treated cells and that supplementation with increasing concentrations of water-soluble cholesterol in 2-DG treated conditions rescues filipin staining signal. B.) Bar charts depicting filipin mean fluorescence intensity per MT4 T cell normalised to vehicle, indicating two-hour incubation of increasing concentrations of oligomycin do not alter surface plasma membrane cholesterol. C.) TZM-bl cells were grown in vehicle (top) or 2-DG-treated (bottom) conditions for two hours after being loaded with LDL-Bodipy staining to label the endosomal compartment. Filipin staining was used to label cholesterol at both the cell surface (red) and LDL-Bodipy (blue) identified regions (green illustrates the LDL-Bodipy associated cholesterol identified by LDL-Bodipy and filipin co-labelling); scale bar 10μm. D.) Bar charts illustrating normalized filipin mean fluorescence intensity in LDL-Bodipy labelled compartments in vehicle and 2-DG-treated conditions (top) and colocalization coefficients of LDL-Bodipy with filipin quantified by z-stacks (bottom). E.) (Left) Bar charts depicting raw filipin mean fluorescence intensity per primary CD4+ T cell in each condition listed. (Right) Representative images of primary CD4+ T cells stained with filipin after treatment conditions listed. Mean values were calculated from at least 50 cells per condition from three independent experiments. \*p\<0.5, \*\*p\<0.01 \*\*\* p\<0.001 as determined by either one-way ANOVA or one-way student's T-test.

(TIF)

###### 

Click here for additional data file.

###### Multiplexed FLIM with SVT reveals no drop in local tension during single HIV-1 fusion in live cells treated with 2-DG.

A.) Compiled MSS lifetimes extracted from whole TZM-bl cells compiled from acquisitions of multiple viral fusion events (green) compared to 2-DG treated cells where viruses were incapable of fusion (blue) or rescued events due to cholesterol treatment (purple). Each point represents a mean of at least 20 cells obtained during three separate experiments. B.) Bar charts comparing the MSS lifetimes of localised regions overlapping with mCherry-labelled HIV-1~JR-FL~ during virion fusion (i.e. mCherry signal loss) with virus-free control areas in the same cell at the timepoint of fusion in TZM-bl cells. Each condition represents a mean of at least 20 cells obtained during three separate experiments \*p\<0.5, \*\*p\<0.01 \*\*\* p\<0.001 as determined by either one-way student\'s T-test C.) Bar charts comparing the MSS lifetimes of localised regions overlapping with mCherry-labelled HIV-1~JR-FL~ (i.e. mCherry signal) with virus-free control areas in the same cell at the timepoint before fusion in TZM-bl cells. Each condition represents a mean of at least 20 cells obtained during three separate experiments \*p\<0.5, \*\*p\<0.01 \*\*\* p\<0.001 as determined by either one-way student\'s T-test. D.) Bar charts comparing the MSS lifetimes of localised regions overlapping with regions where mCherry-labelled HIV-1~JR-FL~ fused with the host cell (i.e. mCherry signal lost) with virus-free control areas in the same cell at the timepoint after fusion in TZM-bl cells. Each condition represents a mean of at least 20 cells obtained during three separate experiments \*p\<0.5, \*\*p\<0.01 \*\*\* p\<0.001 as determined by either one-way student\'s T-test.

(TIF)

###### 

Click here for additional data file.
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###### 

Click here for additional data file.
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Dear Dr Padilla-Parra,

Thank you very much for submitting your manuscript \"Single-cell glycolytic activity regulates membrane tension and HIV-1 fusion\" (PPATHOGENS-D-19-01762) for review by PLOS Pathogens. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the manuscript as it currently stands. These issues must be addressed before we would be willing to consider a revised version of your study. We cannot, of course, promise publication at that time.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.  The use of the most biologically relevant cells always strengthens a body of work so I am sensitive to the concern that most of the work is done with TZM-bl cells.  Also, it is disconcerting that the reviewers had such a hard time following the figures and data. 

In addition, when you are ready to resubmit, please be prepared to provide the following:

\(1\) A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

\(2\) Two versions of the manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Additionally, to enhance the reproducibility of your results, PLOS recommends that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plospathogens/s/submission-guidelines#loc-materials-and-methods>

We hope to receive your revised manuscript within 60 days. If you anticipate any delay in its return, we ask that you let us know the expected resubmission date by replying to this email. Revised manuscripts received beyond 60 days may require evaluation and peer review similar to that applied to newly submitted manuscripts.
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Reviewer\'s Responses to Questions

**Part I - Summary**

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer \#1: This reviewer was looking forward to evaluating this manuscript as corresponding author usually does very nice work. However, this reviewer feels that current manuscript has many claims that are not fully supported by data presented. The major claim (for this reviewer) being the linkages amongst: (i) glycolytic activity; (ii) membrane tension; and (iii) HIV fusion.

It is my opinion that authors have used a sub-optimal system to link the HIV biology with glycolytic activity or membrane tension. Incorporation with relevant T cells data on key aspects would have provided huge amount of reassurance.

In terms of linkage between glyolytic activity and membrane tension, the interesting part begins when FliptR dye is used, BUT the data appear to fell short on definitively making a strong link between glycolytic activity \[metabolism\] and membrane tension (at least for this reviewer).

There is large amount of errors within the manuscript (in particular with figure and supplement figure referrals), which unfortunately make this assessor has (perhaps unnecessary) doubt on some of the work.

Overall, authors have used a lot of cool and exciting techniques in this paper, BUT the authors seem to not have careful considered the limitations of various technique used (at least this is the interpretation of this reviewer). Claims being made in the paper are NOT readily justified in my view. There are fair bit contradictions presented in this revised manuscript that I evaluated (see below).

Overall, authors try to look at the impairment of metabolic effect might have on virus entry. Authors claims that there is a link between metabolic state of the target cell and the ability for the virus to infect. If one takes a simple step back, such premise is not surprising at all. Virus (by definition) hijack host cell system to achieve its own gain. From the point of virus entry, establishment of infection, genetic materials and protein productions, to the stage of assembly of virus, ALL rely on the host cell to be somewhat healthy to begin with - ie metabolic active to generate energy to the rest of the cells, thereby invading virus can take advantage of.

On the other hand, if authors are trying to show a particular subset of metabolic events is purposely hijacked or manipulated by viruses, it would be extremely interesting. To do that, one should demonstrate any observed effect is related to such subset of metabolic events, but the manipulation was NOT affecting the global process (issue of pleiotropic effects).

Unfortunately, in this manuscript, authors have chosen to use a very blunt instruments (in terms of biological systems \[TZM-bl\] as imaging tools are top notch) to demonstrate this point. Authors appear to over-push the imaging technology fronts that this lab is good at, without carefully consider all the limitations (at least this is this assessor\'s opinion). Please see specific comments below.

Having said that, all of these imaging are state-of-the-art techniques. Some time it is less clear for this reviewer whether authors are show-casing these techniques or answering a specific question for this retrovirus.

Key points in summary include the following:

2DG impairing glycolysis, then affect lipid membrane function in association of cholesterol. This could simply be a reflection of a dynamic process in lipid membrane (that requires energy) being important for virus entry?

My own interpretation is that affecting glycolysis could simply be that target cell for infection require the membrane to be healthy (to have dynamic lipid movement) to enable virus to enter. in that sense, if the majority of metabolic process are in idle, it might not be surprising for authors to see these outcomes.

cholesterol-lowering medication in HIV infection is a pretty big stretch by the authors as far as this reviewer is concerned.

From author summary, 'regulating cholesterol' was mentioned. It might not be related to cholesterol regulation on plasma membrane. It is more likely related to maintain dynamic movement of plasma membrane. Observed cholesterol supplement effect could be secondary effect of cholesterol uptake that permits / restores a more dynamic movement of plasma membrane under these \'stress\' conditions.

This assessor has different interpretation from authors on their comments on metabolism, immunity, and viral infection. Authors cited Buck 2017 and Pallett 2019, and I have gone in to read those papers. My personal read is that metabolism needs to be active to allow cell to perform. Likewise, if a cell is dormant and is not doing a lot, it will not be any good to serve immune function to counteract pathogens. Similarly, a less active cell will not be effective for pathogens to infect that lead to production of progeny pathogens. This is different from a sick cell that can still produce energy source, but innate immunity is down. A key issue perhaps is how much the host cells are in idle (80% functional vs 20% functional in energy production). This relationship is particular important for viruses, as viruses rely on host cell machineries to achieve its own gain. Unless the target cells and host cells are \'fairly\' active in generating resource for pathogens to take advantage of, there is not a lot of use for viral pathogens. I think we all agree that biological process requires energy in one form or the other.

The entire infection process requires energy, and viruses DO NOT bring in its own energy production source. The simple explanation (that authors observed) is an effect at the entry stage of virus-cell interaction, which reflects the very first step of energy expenditure process that virus relies on the host cells - ie entry.

Authors described hemi-fusion event and membrane curvature in an attempt to link cholesterol in HIV infection. However, the system that the authors used also including the VSV-G HIV system, which is unrelated to HIV Env. VSV-G mediated endocytosis entry is largely unaffected by cholesterol (at least with particle-associated cholesterol, and I recalled at least 3 labs have independently reported this). On that note, making it more difficult for the authors to link their story with cholesterol specifically. Again, to me, the phenotype is more likely a general impact on metabolism. More concerns about hemifusion events are described below.

With PLoS Pathogens, there is NO limit on numbers of figures or word count. There are many supplement figures in this paper should be incorporated as main figures. Authors should correct this before publication. Authors claim current format is intended to be helpful for readers, and I do not share their enthusiasms. It looks though other reviewer is feeling the same. Current formats appear to be something originally submitted to another journal (eLife for example), and this format is not helpful in my opinion. in fact, there are A LOT of errors within this current manuscript that is very damaging to the paper (see specific below).

Reviewer \#2: Coomer et al. report a beautiful study of the importance of the properties of the target membrane on HIV fusion, and its link to the metabolic state of the cell. They find that reduction in glycolysis removes cholesterol from the plasma membrane, which increases membrane tension. This increase in tension is less favorable for HIV fusion. As a result, virions entering at the plasma membrane stall at the hemifusion stage, as evidenced by observation of lipid mixing in the absence of content release. While the importance of target cell metabolic state and the physical properties of the membrane have previously been reported as important to HIV fusion, this study makes clear the inter-relatedness of these previous observations and generates a more unified understanding.

As one has come to expect from the Padilla-Parra laboratory, the authors use quantitative optical microscopy approaches, and a variety of fluorescence-based assays, which appear to be rigorous and well executed. By my evaluation, the previous reviewers were appropriately thorough; and the authors have nicely addressed all major points raised. I therefore have only minor comments.

Reviewer \#3: Overall, I thought this was an interesting paper. I think the assays that the authors have used are clever and allow them to begin to answer very difficult questions in our field. I particularly liked the coupling of the FLIM images with infectivity assays and fusion reporters in non-treated cells, since as the authors mentioned, the experiments are internally controlled and the metabolic pathways of the cells are not perturbed. At times, I wish the data they presented were a bit cleaner, but the statistics look good. The biggest frustration I had with this paper was the number of errors in labeling and writing. These errors made important parts of the paper very difficult to decipher, and at times, I was left wondering if I interpreted their errors correctly and was understanding the data properly. To be honest, I am not someone who often picks up on these types of errors, so the fact that I found so many suggests that it's a significant problem. The authors need to read this paper VERY carefully and correct all errors.

\*\*\*\*\*\*\*\*\*\*

**Part II -- Major Issues: Key Experiments Required for Acceptance**

Please use this section to detail the key new experiments or modifications of existing experiments that should be [absolutely]{.ul} required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a \"Major Revision\" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend \"Reject\".

Reviewer \#1: Figure 1 TZM-bl. TZMB1 spreads out very well, and they are excellent for cell morphology in terms of imaging. TZM-bl are also very tough-resilient, and they are not real cells for HIV infection. MT4 is good, but still limited. For the claim to be linked with HIV, it would be necessary for author to repeat figure 1A with PBMCs (2-DG dose response) along with cell viability. Maximum impact is 50% reduction of infectivity with VSV-G pseudo typed HIV. I wonder what the impact it would be using PBMCs and R5-tropic (or even transmission strain HIV) to infect. The key concern is that the 2-DG treatment described was way too tough to the host cell to begin with. By impairing the major metabolic processes to the host cells, these cells are essentially too weak (perhaps even dying) to do anything, therefore not able to support HIV infection as consequence. If authors insist on their claim with HIV, I think it is only fair that they have appropriate T cell infection data.

On the other hand, if authors were changing their claims, experiments in T cells might not be needed. More specifically, the beautiful imaging data are excellent. To me, they demonstrate to me that energy requirement is needed to have a dynamic membrane (including cholesterol movement). Such dynamic movement of plasma membrane as well as membrane related endocytosis process are fundamental for particles uptakes. What authors are seeing in both HIV particles in TZMBL and VSV-G HIV in TZMBL are reflection of that. This could well be a general principle for particles uptake (including many viruses and perhaps even exosomes). Such general principle could be best demonstrated using various viral envelope pseudotyped particles (Zika Env, SARS Env, Ebola Env and VSV-G to just named a few) plus a number of other relatively easy to image fibroblast typed cells. Authors can even use the exact same imaging system that they have right now.

Legends in Figure supplement Figure 1A are not adequate. Which one is HIV-1(VSV-G) or HIV-1(NL4-3)? Is VSV-G on top of NL4-3 or VSV-G on top of Envelope negative HIV? In fact, the presentation of supplement Figure 1A is not up to usual standard of this team. I would imagine authors should synchronise all fonts and font size throughout all figures (including supplement) to deliver their points to reviewers in order to help to demonstrate their case effectively, as well as best to illustrate the quality of works being done. Presentation of supplement figures are no less important from the main figures.

With Figure 1 supplement figure 1B, is that laconic or perceval? Similar question with supplement figure 1d. what is on the label with this supplement figures vs what is written in the supplement figure legends are completely opposite - which one is the truth? Same question for Supp Fig1E vs Supp Fig1F. Noticed author rebuttal, but I am not sure error has been corrected - at least with the version I have.

Authors should have better explain what the oligomycin control is used for, and what that meant. Currently, it is very inadequate in this assessor\'s view

With the schematic on Fig 1C and the ACTUAL data in Fig1 Suppl Fig1F-H, authors seem to suggest the metabolic state of the cell are significantly affected by 2-DG. With this in mind, would it not true a simple explanation being that the 2-DG treated cells are now so weak to produce energy source that virus can no longer hijack the cellular machineries to establish infection? A trivial and simple explanation. An important character of virus being that it relies on host cell to replicate, and the key issue for that being virus cannot generate its own energy source and metabolically inert.

Arguments made by authors from lines 142 to 152 are not interpretable given the conflict of figure 1 supplement figure 1B-E legends

With limitation / conflict of figure 1 supplement figure 1B-E legends, paragraph from line 153 to 161 are not easy to understand

At the first glance, data in Fig 2 are really cool set up and experimental approaches. However, the choice of using TZM-bl cells appears to be a waste opportunity for this assessor. Only if authors apply these in more relevant cells. Just because TZM-bl are easy to image, it does not mean that TZM-bl is best for the current biological question in hand (see below with more details or above for tailoring claims against data presented).

With Vpr-b-lam assay, the enzyme b-lam is from virion, substrate CCF2 is passively introduced (does not require metabolic events of the target cells). There are a lot of HIV 'fusion' events seen in 2B. What is the background level of b-lam activity with this batch of TZM-bl cells of the authors. TZM-bl or HeLa are well known engineered cells, TZM-bl (and HeLa) can vary from one lab to the next, early day cell engineering often utilise plasmid contain ampicillin resistant gene (blaTEM-1). It would be great (in fact important) for authors to confirm their TZM-bl cells to have low background of b-lam gene products (without HIV infection) to reassure their observations of red (presumed fusion events) are indeed related to HIV entry (therefore releasing b-lam from Vpr-conjugation). This assessor has seen data of different TZMbl used for b-lam entry assay with significant different levels of backgrounds. Authors should clarify this. There is a scale bar in second panel of 2b, but actual scale was not described in the legend.

With data in Figure 2, authors suggest that low metabolic activities are related to lower fusion events for HIV entry. Here is an alternative interpretation. Assuming that there is background b-lam issue with the TZMBl cells being used, therefore it is possible that lower metabolic activity would lead to less endogenous b-lam being expressed, hence, loading of CCF2 dye will give rise to less portion of red (presumed fusion positive cells), while adding HIV into these cells will lead to smaller fraction in terms of changes to 'presumed fusion positive states'. Authors could still be correct, but these alternative possibilities must be eliminated. Also, TZM-bl is great for endocytosis mediated entry (which are also supported by data presented by this team). At the end of the day, best possible controls please;

From the paragraph starting in line 177, authors indicated that treatment of 2-DG does not affect viability of cells based on propidium iodine staining. Two questions emerge: (i) is propidium iodine staining the best assay for this? As described above, what if the cells have become SO fragile / weak that are no longer able to support most of their biological activities due to not making enough ATP (but they are not yet dead). As a consequence, much of the mechanism viruses rely on to infect the host are no longer available. These top down overall effects on shutting down metabolic process would complicate interpretation. In the case the propidium iodine staining, the cells HAVE to be dead in order for the dye to go in, hence it is not fair to say that 2-DG does not have toxic effects to the cells. These cells are likely to be so weak but not dead JUST YET -- would you not consider this cytotoxic effect or pleiotropic effect? (I would); (ii) Also, HeLa based cells (including TZMbl) are generally MUCH tougher than many other cell types in the lab, making the thresholds of picking up propidium iodine stains much higher. This reviewer would suggest that parallel experiments should be done on primary T cells to begin with, in particular given authors' claim on potential clinical application by extrapolating these observations on cholesterol lowing medication in HIV infection (assuming HIV linkage remains a key claim from the reviewers).

Another way to look at it would be dynamic movement of lipids (including cholesterol movement in PM) requires energy. What authors have observed (impacts on HIV entry in TZMBl cells) is simply reflection of this defects. In the other word, the phenomenon with HIV entry is a real out of plasma membrane dynamics, but not a SPECIFIC event that is unique to HIV. Perhaps consider showing this as general principle for various particles uptake (including exosomes across larger number of fibroblast cell types? General principle seems to be more important to me than HIV infection.

By the way, if authors feel that they are correct that cholesterol lowering drug can impact on HIV replication in a way that they suggest, perhaps they should simply do that experiment using primary cells and physiological relevant dosage of cholesterol lowering drugs to see whether HIV entry is affected based on their hypothesis. If their claim is true, it will be a much stronger paper using these high-end imaging approaches to show the HIV linkage and increase accuracy of their prediction / hypothesis.

For information in line 182, it has been reported that with the endocytosis mediated HIV entry, the cholesterol (at least particle-associated cholesterol) in VSV-G pseudotyped HIV is NOT important for virus entry (reported by multiple labs). On the surface, current interpretation of the authors is not in line with what the field knows. However, this reviewer agrees that whether overall cholesterol levels in the host cells is important for VSV-G pseudotyped HIV can affected endocytosis mediated entry is not known. The main reason (in my opinion) such information is hard to emerge as the pleiotropic effects of such manipulation on the entire cell, making it impossible to properly interpret some of those experiments. As far as I know, there is NO simple / clean way to manipulate cholesterol on PM without affecting other parts of the cells. This assessor feels that the authors are facing similar problems with their claims here on metabolic activity. Unless there is a way to ISOLATE a specific effect on cholesterol regulation at the plasma membrane alone from manipulate metabolic process, proper interpretation would be difficult.

Would have been good if there is a figure number (1, 2, 3, ...) in all of the figures and supplement figures. While authors might have label individual figure file with such info, this information is missing in the merged file. This is particular important that all supplement figures are all group together, but there is NO supplement figure 2. For example, there are Figure 1 supplement 1, then jumped to figure 3 supplement 1 and figure 3 supplement 2. This information was not obvious until this assessor has gone through the legends of supplements -- unnecessary confusing and annoying! Anything helps reviewers to better understand the paper is a good thing (in my opinion). On the same points, authors are extremely careless in describing and citing their figure number in the text. Very often, author mis-referred to figures, and I was not able to find all figures mentioned. Given this is already a revision, it is a bit concerning.

Line 186 on (supplement Figure 3B) is not clear. Do author mean Figure 3 supplement 1B or Figure 3 supplement 2B.

If authors refer to Figure 3 supplement 1B for comments in Figure 3 supplement 1B, yes, I can see that is statistically significant with \*. However, judging from the error bar, it is almost overlapped, and the p-value must be just under 0.05. What if you do that experiment with more biological relevant cells for HIV -- ie PBMCs, where entry numbers will be low, and more sensitive to damage by these types of treatments. I wonder what the p value be then.

Label in Figure 3 supplement 1C are WAY too small. Again, line 191, wording of 'supplemental Figure 3C' was not clear enough for Figure 3 supplement 1C or Figure 3 supplement 2C. Reviewers and audience should not have to guess or to assume.

With figure 3 supplement 2c, co-labelling experiment to look at hemifusion using iGFP and DiD dye. Authors should be congratulated on doing these experiments, as they are tough experiments. However, I would suggest the N values of these are limited. Notwithstanding that these are very tough experiments, but from the vantage point of reviewer, I would ask the question whether these numbers are sufficiently significant to demonstrate the claim, rather than the level of difficulty of these experiments themselves. Also, authors use TZM-bl system. Why not primary T cells or even T cell line? I seem to recall live imaging of T cells have been done by highly respectable scientists at Oxford some years ago. Would they not be near by the authors' lab? At least you are all at same University. Furthermore, the upward time (shown) for imaging is 10min that have been done by this team. Understand the nucleus are huge in T cells, BUT since the question is about PM based entry anyway, there will not be a major issue. T-cell experiments would be much more convincing for claim linking with HIV infection.

No question that there are many very cool and advance technologies throughout utilised by the authors, but cart should not come in front of the horse. Even with large number of COOL technologies, if biological question cannot be answer properly in the stated claim with the data presented, arguments will fall down. The only exception would be if that is a technological paper to begin with, but this is not the case here. I feel the authors \'overplay\' their technology card

From lines 202 to 228, there are A LOT of works here. These are also difficult experiments. I also understand that spin-inoculation will help the number to go up for measurement purpose. Personally, I would have been much more interested to see the 'Not-Spun' virus infection experimental data, bright green of Figure 3 supplement 2C. From the text, authors seem to indicate that the data from Main Figure 3C are for non-SPUN virus SVT, perhaps it will be good to remove SPUN virus data from Figure 3 supplement 2 to avoid confusion.

Line 205 'Supplemental figure 3D' meant 'Figure 3 supplement 1D' as seen with legend?

Line 215 'Supplemental figure 3E' meant 'Figure 3 supplement 1E' as seen with legend?

In 'Figure 3 supplement 2C', the distinct categorisation between 'hemifusion' and 'colour separation' are not clear. According to description on line 213-217, there are two types of DiD dye disappearance events. One is 'near-asymptotic loss', while the other one is slow DiD decay. Authors clearly indicated that 7% of rapid decay (colour separation) was previously reported in Vega et al 2011. If I am not mistaken what I have read in the Vega et al paper, the fast decade of DiD (7%) in this case, was referred to be evidence of 'hemifusion' event in the last paper (see Vega et al 2011, under Section of 'Results', Sub-Section of 'Blocking HIV-1 uptake by a dynamin inhibitor ...', the last two sentences of Paragraph, and I quote

'These findings are consistent with the notion that the slow loss of DiD fluorescence is caused by dynasore, whereas the fast DiD decay reflects transfer of viral lipids into the plasma membrane mediated by Env. By definition, lipid mixing in the absence of content release corresponds to a hemifusion phenotype.

If these rapid DiD lost event WAS related to hemifusion event before in the Vega paper, why would authors CHANGE the definition NOW that in this MANUSCRIPT that 'Hemifusion is related to the slow release of DiD dye?

Authors MUST clarify the distinction between hemifusion vs colour separation.

Also, given data in Figure 3 supplement 2C that authors clearly have the capacity to distinct different categories of dye disappearance (endosomal fusion, hemifusion, colour separation and plasma membrane fusion), author should (and perhaps MUST) present their main Figure 3C data (with vs without 2DG treatment) that way (ie with these 4 categories - endosomal fusion, hemifusion, colour separation and plasma membrane fusion). These would be MUCH MORE meaningful. It is VERY puzzling that authors have not done that AND make the assumption and I quoted

'it is extremely likely that the observed hemifusion arrest by 2-DG explicitly occurs in the plasma membrane' (see line 227-8). This assumption does not seat well with this reviewer. Would authors like to see other manuscript present their major claim of the paper (as seen in abstract and title) basing on an assumption? This is particularly puzzling given the data are within the reach of the authors, and the experiments are high quality.

On line 223, authors suggested there is (supplement figure 4, related to figure 3). Again, the labelling of figures by authors are poor. I could be wrong, but I was not able to find a supplement figure that is related to spun and non-spun data.

On line 224, authors claim that PM fusion occurs in a high probability. However, the data in Figure 3 supplement 2 C , there are more endosomal fusion events.

Under section of 'Single-Cell Metabolic State is linked to ... ...', line 230, authors use filipn stain to quantify cholesterol. Stain-ability by filipn is a very indirect way to quantify cholesterol on PM. Why not use mass spec by isolating the membrane fractions?

Lipid membrane in PM is dynamics, binding of cholesterol with filipin will OF COURSE affecting PM architecture. This reviewer disagrees with comments made in line 237 by authors. I am surprised authors will cite a book chapter published in 2019 (which I do not have access due to non-open access to verify the authors' claim from this book). I however do notice that authors have ignored large number of papers and reviews published on lipid rafts and filipin in the past 20+ years. A simple search would have revealed filipin effects on plasma membrane of cells are cell type dependent and concentration dependent. By searching the entire submitted manuscript, authors did not indicate the flipin concentrations used, nor provide control data showing their flipin labelling does not adversely affect the host cells in their hands.

The MBCD treatments described between lines 239 and 246 are irrelevant to me. In the presence of mixing filipin as a stain, then MBCD, there will be too many effects on the PM, making things way too complicate to interpret. In fact, MBCD will cause cholesterol shuttling between PM and extracellular environment much more rapid.

In my opinion, exogenous cholesterol supplement experiment is poorly designed. When exogenous cholesterol is introduced into cell, it will promote cholesterol uptake by cells. If the overall metabolic events of the cell are affected, and impacting on normal cholesterol synthesis then PM targeting, exogenous cholesterol can easily be picked up by host cells from extracellular environment. As a consequence, virus particles such as HIV can readily be picked up -- Brugger et al 2006 PNAs already described HIV essentially is a specific type of rafts. Consequently, data in Figure 2C are therefore completely expected for this reviewer -- but not for the reason authors thought or claimed.

Authors indicated there is figure 4D (line 253), but this assessor cannot find figure 4D

This assessor does not know enough about the FliptR dye. However, would one approach be enough to establish an important claim between metabolic events and membrane order? Notwithstanding some of the limitation of the Laurdan, why not use it to provide additional data to strength the claim? In particular, potential coupling with PALM/STORM on CD4 as others have done on LAT (Owen 2012 Nat Comm).

Reviewer \#2: (No Response)

Reviewer \#3: 1. I believe that Supplemental Figure 1 is still not correct. I think Figures 1C and 1E need to be flipped --- they do not correspond to the graphs in 1B and 1C. Also, the figure legends for 1B and 1C do not correspond to the labels in the figure. Especially since the two metabolic reporters show opposite trends, these errors made interpreting Main Figure 1D very hard. However, I think I figured it out and that the data in the main figure make sense.

2\. I think the author's should give better descriptions of their reporter assays. Most HIV readers will understand the assays, but the article should be accessible to others. For example, in Figure 2A, they show the chemical reaction that is catalyzed but don't explain why a vpr-blam fusion would be a marker for viral entry. The descriptions should be brief but the reader shouldn't have to go to other references to understand the basis of the assays.

3\. With regards to the sometimes poor overlap of cells in the different images in Figure 1 and 2 that the previous reviewer mentioned. The authors arguments make sense, but would it be possible to include transmission images of the cells before and after? It might make it more obvious that the same cells are being imaged and how they have changed. Also, in Figure 2C, it would be helpful if there were images of regions with lower cell density so that the cell identities would be more obvious.

4\. Why does the image in Figure 4C w/ 400ug/mL of cholesterol have so many non-infected cells? It appears from the graph that the infection rate should be much higher.

5\. The authors should consider moving some of the supplemental data into the main figures. Specifically, I found the Flipper-TR data to be clean and convincing and think it should have a more prominent place in the paper.

6\. I think that the authors need to address the effects of cholesterol on the endosomal membrane. Even in their "no spin" experiments, a significant portion of fusion events appear to go through the endosome. If they're trying to correlate infectivity with membrane effects then they need to show convincing data that perturbations that they make to the plasma membrane have similar effects on the endosomal membrane.

\*\*\*\*\*\*\*\*\*\*

**Part III -- Minor Issues: Editorial and Data Presentation Modifications**

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer \#1: No additional comments

Reviewer \#2: It is worth commenting on whether glycolysis is likely to affect plasma membrane composition beyond cholesterol.

Why is Figure 1C largely repeated in Figure 2A? This seems unnecessary.

At several points throughout the figures (e.g. Figure 2B) histograms are presented along side example images. The axes of the histograms are not labeled, and they are not defined in the legend, making them difficult to interpret for the unfamiliar reader.

On line 253, the authors refer to Figure 4D. Figure 4 only has panels A through C.

In the model in Figure 6 the hemifusion arrested state is depicted in an unusual way, with the inner leaflet of the viral membrane disrupted. Typically, the inner leaflets are thought to be intact in the hemifusion state. Was this intentional? If not, I would suggest drawing this in the conventional way so as to avoid confusion.

Reviewer \#3: 1. The G and H figure legends are also swapped in Supplemental Figure 1. In the legend it says that the G graph corresponds to 2-DG, while in the figure it is labeled Oligomycin.

2\. Supplemental Figure 2 is mislabeled Figure 3 in the figure legend.

3\. I'm assuming in Supplemental Figure 3C that this is not "%" but "fraction"? 0.25% seems very low.

5\. I believe the MT-4 panel of cell images is missing in Figure 4.

6\. Some of the labels are cutoff in Supplemental Figure 4A.

7\. The authors should label the graphs in Supplemental Figure 5F.

8\. Supplemental Figure 6 is mislabeled Figure 5 in the figure legend.

9\. The authors should consider labeling more explicitly the figures themselves. It's frustrating to have to constantly dig through figure legends to understand what the graphs are showing.

\*\*\*\*\*\*\*\*\*\*
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Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer \#1: A very comprehensive revision, and it is certainly one of the more detailed revisions I have seen in recent time. Thank you.

Reviewer \#3: This paper describes a study that explores an important problem in our field. The experiments in the paper are well-done, and the conclusions are novel and very interesting. In addition, the authors have addressed my concerns in this revised manuscript.

\*\*\*\*\*\*\*\*\*\*

**Part II -- Major Issues: Key Experiments Required for Acceptance**

Please use this section to detail the key new experiments or modifications of existing experiments that should be [absolutely]{.ul} required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a \"Major Revision\" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend \"Reject\".

Reviewer \#1: Not Applicable

Reviewer \#3: None
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